# Chapter 113: Sedative, Hypnotic, or Anxiolytic Intoxication

## The Biological and Neurological Basis of Sedative, Hypnotic, or Anxiolytic Intoxication

## Introduction

Sedative, Hypnotic, or Anxiolytic (SHA) Intoxication is a substance-induced disorder characterized by clinically significant maladaptive behavioral or psychological changes that develop during, or shortly after, use of substances such as benzodiazepines, barbiturates, and related drugs (Daley & Douaihy, 2019; Sarkar et al., 2023). According to the International Statistical Classification of Diseases (ICD), intoxication is defined as a transient condition following substance administration that results in disturbances in consciousness, cognition, perception, affect, or behavior (Sarkar et al., 2023). The clinical presentation of SHA intoxication exists on a dose-dependent continuum of central nervous system (CNS) depression (Tseng et al., 2020; Sarkar et al., 2023). In small doses, these agents alleviate anxiety (anxiolysis); in moderate doses, they induce calmness and sleep (sedation and hypnosis); and in large doses, they can produce profound CNS depression leading to anesthesia, stupor, coma, and potentially fatal respiratory depression (Tseng et al., 2020; Nahas-Vigon & Fingerhood, 2025; Ciszowski & Mietka-Ciszowska, 2013).

The hallmark features of intoxication include slurred speech, motor incoordination, unsteady gait, impaired judgment, and cognitive deficits in attention and memory (Fingerhood, 2020; Nahas-Vigon, 2025). These disturbances can lead to significant impairment in social and occupational functioning and increase the risk of accidents (Edwards, 1995; Gull & Langford, 2006). While typically characterized by CNS depression, SHA intoxication can also manifest with paradoxical reactions, including disinhibition, emotional lability, agitation, aggression, and even psychosis, which may complicate the clinical picture and management (Breggin, 1998; 倉田明子 et al., 2011; Sarkar et al., 2023).

The biological basis of SHA intoxication is rooted in the modulation of key neurotransmitter systems responsible for regulating arousal, cognition, and motor control. The primary mechanism for the most commonly used sedatives, such as benzodiazepines and barbiturates, involves the potentiation of the brain's main inhibitory neurotransmitter, gamma-aminobutyric acid (GABA) (Tseng et al., 2020; Nishino et al., 2017). This enhancement of GABAergic neurotransmission produces a widespread dampening of neuronal activity across various brain regions, from the brainstem arousal centers to the cerebral cortex (Winters, 1976; Tseng et al., 2020). The specific phenomenology of intoxication is further shaped by the drug's unique pharmacokinetic and pharmacodynamic profile, individual genetic and metabolic factors, the patient's age and developmental stage, and the presence of comorbid medical or psychiatric conditions (Nelson & Chouinard, 1999; Buckley, 2007). This chapter will provide a comprehensive overview of the biological and neurological mechanisms that underlie the complex clinical syndrome of Sedative, Hypnotic, or Anxiolytic Intoxication, drawing exclusively upon the provided body of research.

## Neurobiological Systems

The diverse clinical manifestations of SHA intoxication—ranging from anxiolysis and sedation to cognitive impairment and motor incoordination—are a direct consequence of the drugs' effects on fundamental neurobiological systems. These substances primarily act by altering the delicate balance between excitatory and inhibitory neurotransmission throughout the central nervous system (CNS) (Söderpalm, 2002; Antonio & Alfredo, 2012). The most critical system involved is the GABAergic system, though interactions with dopaminergic, serotonergic, and other neuromodulatory pathways contribute to the full spectrum of intoxication effects, including abuse liability and paradoxical reactions (Roques, 2000; Feighner & Boyer, 1989).

### The Central Role of the GABAergic System

The vast majority of sedatives, hypnotics, and anxiolytics, including benzodiazepines, barbiturates, and the "Z-drugs" (e.g., zolpidem, zopiclone), exert their primary effects by enhancing the function of the gamma-aminobutyric acid (GABA) system (Tseng et al., 2020; Nishino et al., 2017; Elhassan et al., 2018). GABA is the principal inhibitory neurotransmitter in the mammalian brain, and its activity is crucial for regulating neuronal excitability (Söderpalm, 2002; Shul'gina, 2011). These drugs act as positive allosteric modulators at the GABA-A receptor, a ligand-gated chloride ion channel complex (Tseng et al., 2020). By binding to distinct sites on the receptor, they increase the affinity of GABA for its own binding site, thereby potentiating its natural inhibitory effect (Nishino et al., 2017). This potentiation leads to an increased influx of chloride ions into the neuron, causing hyperpolarization of the cell membrane and making it less likely to fire an action potential (Tseng et al., 2020). This widespread neuronal inhibition is the fundamental mechanism underlying the CNS depressant effects of these drugs (Sarkar et al., 2023; Fingerhood, 2020).

The global distribution of GABA-A receptors throughout the CNS explains the broad spectrum of effects seen in intoxication (Tseng et al., 2020). Inhibition of neuronal circuits in the brainstem's reticular activating system is responsible for sedation, hypnosis, and, at high doses, coma (Winters, 1976; Horton, 1980). In the limbic system, particularly the amygdala, enhanced GABAergic tone produces the anxiolytic effects for which these drugs are often prescribed (Söderpalm, 2002). Effects on the hippocampus contribute significantly to the anterograde amnesia—the inability to form new memories—that is a common and often problematic side effect of intoxication (Ohta, 1996; Breggin, 1998; Nelson & Chouinard, 1999). Meanwhile, suppression of neuronal activity in the cerebellum and basal ganglia leads to the characteristic motor symptoms of intoxication, such as ataxia, dysarthria (slurred speech), and general motor incoordination (Sarkar et al., 2023; Nahas-Vigon, 2025). Finally, inhibition of cortical circuits, especially in the prefrontal cortex, results in cognitive impairments, including poor concentration, slowed thinking, and impaired judgment and impulse control (Ramey & Regier, 2018; Nahas-Vigon, 2025).

### Interaction with the Dopaminergic Reward System

While the primary effects of many SHAs are inhibitory, their abuse and addiction potential are linked to their indirect effects on the brain's dopaminergic reward pathways (Roques, 2000; Beninger, 2018). The mesolimbic dopamine system, originating in the ventral tegmental area (VTA) and projecting to the nucleus accumbens (NAc) and prefrontal cortex, is central to processing reward, motivation, and reinforcement learning (George & Koob, 2017; Antonio & Alfredo, 2012). Dopaminergic neurons in the VTA are themselves under the inhibitory control of local GABAergic interneurons. By enhancing the effect of GABA on these interneurons, sedative-hypnotics can disinhibit the dopamine neurons, leading to an increased release of dopamine in the NAc (Antonio & Alfredo, 2012). This surge in dopamine produces feelings of euphoria and reinforces drug-taking behavior, forming the neurobiological basis for psychological dependence and addiction (Clay et al., 2008; Sanchis‐Segura & Spanagel, 2006). This mechanism helps explain why substances primarily known for their depressant effects can be sought for their pleasurable or "high" effects, contributing to patterns of misuse, abuse, and dependence (Ciraulo & Ciraulo, 2008; Vanderschuren, 2008).

### Modulation of Other Neurotransmitter Systems

While the GABA-dopamine interaction is key, other neurotransmitter systems are also relevant to the broader class of anxiolytics and hypnotics. A newer class of anxiolytics, exemplified by buspirone, acts primarily as a partial agonist at serotonin 5-HT1A receptors, producing anxiolytic effects without the sedation, cognitive impairment, or dependence liability associated with benzodiazepines (Feighner & Boyer, 1989; Eison, 1989). This highlights that anxiolysis can be achieved through non-GABAergic pathways.

Furthermore, many drugs used for their sedative side effects act on other systems entirely. For instance, certain antidepressants like trazodone and mirtazapine are prescribed off-label for insomnia due to their potent antihistaminic and, in some cases, serotonergic (5-HT2A antagonism) properties (Goldenberg, 2003; Riemann, 2014; Kallweit et al., 2023). The sedative effects of first-generation antihistamines (e.g., diphenhydramine) are also mediated by their blockade of central histamine H1 receptors, a system crucial for maintaining wakefulness (Mathias et al., 1988; Bourin et al., 2002).

Emerging hypnotic agents target novel systems. Melatonin receptor agonists, such as ramelteon, promote sleep by acting on MT1 and MT2 receptors in the suprachiasmatic nucleus, the brain's master circadian clock (Neubauer et al., 2008; Kallweit et al., 2023). More recently, orexin receptor antagonists (e.g., suvorexant) have been developed; by blocking the wake-promoting signals of the orexin/hypocretin system, these drugs facilitate the transition to sleep via a mechanism distinct from global CNS depression (Nakamura & Inoue, 2015; Kallweit et al., 2023). While intoxication with these newer agents may present differently from classic GABAergic sedatives, they underscore the diverse neurochemical pathways that can be modulated to produce sedation and hypnosis.

## Genetic and Molecular Basis

The variability in individual responses to sedative, hypnotic, and anxiolytic drugs, including the severity of intoxication and the propensity for dependence, is influenced by a complex interplay of genetic and molecular factors. While the provided research does not contain specific gene-association studies for SHA intoxication, it offers a framework for understanding the biological underpinnings of this heterogeneity, focusing on the heritability of substance use disorders, pharmacogenomic variations in drug metabolism, and the molecular machinery of receptors and signaling pathways.

### Heritability of Substance Use Disorders

A predisposition to developing substance use disorders (SUDs), including those related to sedatives, hypnotics, and anxiolytics, is known to have a significant genetic component (Daley & Douaihy, 2019). Family, twin, and adoption studies have consistently shown that vulnerability to addiction is heritable (Cadoret & Winokur, 1972). This genetic vulnerability may manifest through various mechanisms, such as inherited differences in the brain's reward circuitry, personality traits like impulsivity or neuroticism, or a predisposition to comorbid psychiatric conditions like anxiety and depression, which are themselves risk factors for sedative use (Buckley, 2007; Rohde et al., 1991; Smith et al., 2010). For example, genetic factors may underlie individual differences in the mesolimbic dopamine system, rendering some individuals more sensitive to the reinforcing effects of drugs (Clay et al., 2008; Roques, 2000). While these principles apply broadly to SUDs, it is highly probable that they extend to the specific risk of developing dependence on SHA drugs (Daley & Douaihy, 2019).

### Pharmacogenomics and Individual Variability

Genetic factors also play a crucial role in pharmacokinetics, determining how an individual's body processes a drug. Polymorphisms in genes encoding metabolic enzymes can lead to significant variations in drug clearance, affecting both the intensity and duration of intoxication (Nelson & Chouinard, 1999). For instance, the cytochrome P450 (CYP) enzyme system is responsible for the metabolism of many psychotropic drugs (Andrade, 2012). Although not specific to sedatives in the provided literature, the example of CYP2D6 genetic polymorphism, which creates ultrarapid, extensive, intermediate, and poor metabolizers of drugs like venlafaxine, illustrates a critical principle (Petit & Sansone, 2011). An individual who is a "poor metabolizer" for a specific sedative would experience higher-than-expected plasma concentrations and a prolonged drug half-life from a standard dose, leading to more profound intoxication, increased risk of toxicity, and greater cognitive and psychomotor impairment (Unknown, 2010). Conversely, an "ultrarapid metabolizer" might experience a shorter duration of action, potentially leading to inter-dose withdrawal symptoms and a drive to use the drug more frequently (Petit & Sansone, 2011). This variability in drug metabolism contributes significantly to the heterogeneity of clinical presentations of intoxication (Nelson & Chouinard, 1999).

### Molecular Mechanisms at the Receptor Level

The primary molecular targets for benzodiazepines, barbiturates, and Z-drugs are the diverse subtypes of the GABA-A receptor (Tseng et al., 2020; Nishino et al., 2017). These receptors are pentameric protein complexes assembled from a large family of subunits (e.g., α, β, γ). The specific combination of these subunits determines the receptor's pharmacological properties, including its affinity for different drugs and its location within the brain (Hertz et al., 2014). For example, newer hypnotics have been developed with selective affinity for the α1 (omega-1) subunit of the GABA-A receptor, which is thought to mediate sedative effects with less impact on muscle relaxation and cognition compared to non-selective agents (Ohta, 1996; Nakamura & Inoue, 2015). Genetic variations in the genes encoding these subunits could theoretically alter an individual's sensitivity to a drug, predisposing them to more severe intoxication or, conversely, to a weaker therapeutic or adverse response.

### Molecular Basis of Neuroadaptation

Chronic exposure to SHAs triggers neuroadaptive changes at the molecular level, which underlie the phenomena of tolerance and dependence (Goldstein, 2001; Tseng et al., 2020). Prolonged agonism at GABA-A receptors can lead to a compensatory downregulation of the receptors themselves or a change in their subunit composition, rendering the neuron less sensitive to both the drug and endogenous GABA (Tseng et al., 2020). This process, a form of synaptic plasticity, necessitates higher doses of the drug to achieve the original effect (tolerance) (Fava & Cosci, 2019). At the level of gene expression, chronic drug use can induce lasting changes through the modulation of transcription factors. For example, the accumulation of transcription factors such as ΔFosB in response to chronic drug exposure is believed to mediate long-term changes in neural plasticity that contribute to the sensitized responses and compulsive drug-seeking behavior characteristic of addiction (Antonio & Alfredo, 2012). These molecular alterations are central to the transition from controlled use to a substance use disorder and are the basis for the physiological withdrawal syndrome that emerges upon drug cessation (Becker & Redmond, 2002).

## Brain Structure and Function

Sedative, hypnotic, or anxiolytic intoxication is fundamentally a state of global CNS dysfunction, manifesting through a cascade of effects on discrete brain regions and the neural circuits that connect them. The widespread distribution of GABA-A receptors ensures that these drugs impact nearly all aspects of brain function, from brainstem arousal mechanisms to higher-order cortical processing (Tseng et al., 2020). The resulting clinical picture of intoxication reflects the hierarchical suppression of these systems in a dose-dependent manner.

### Brain Regions and Neural Circuits

The descent into deeper levels of intoxication can be mapped onto the progressive inhibition of specific brain structures. Initial anxiolytic effects are largely mediated by the suppression of hyperactivity in the limbic system, particularly the amygdala, which is central to processing fear and anxiety (Söderpalm, 2002; Antonio & Alfredo, 2012). As doses increase, sedative and hypnotic effects emerge, primarily through the inhibition of the ascending reticular activating system (ARAS) in the brainstem (Winters, 1976; Horton, 1980). The ARAS is a diffuse network of nuclei responsible for maintaining cortical arousal and wakefulness; its suppression is a key mechanism for inducing sleep and, at higher doses, anesthesia and coma (Horton, 1980; Ciszowski & Mietka-Ciszowska, 2013).

Motor impairments, such as ataxia, dysarthria, and poor coordination, are hallmarks of SHA intoxication and are attributable to the disruption of cerebellar function (Sarkar et al., 2023; Tseng et al., 2020). The cerebellum is critical for coordinating voluntary movements, posture, and balance, and its dense population of GABAergic neurons makes it highly sensitive to the effects of these drugs (Tseng et al., 2020). Similarly, effects on the basal ganglia, another key motor control center, can contribute to psychomotor retardation and slowed movements (Dodd, 2007; Bains et al., 2021).

Cognitive deficits are a prominent feature of intoxication. Anterograde amnesia, the inability to form new memories while under the drug's influence, is strongly linked to the inhibition of the hippocampus, a temporal lobe structure vital for memory consolidation (Ohta, 1996; Breggin, 1998; DeJong, 1969). Broader cognitive impairments, including deficits in attention, concentration, judgment, and executive function, arise from the suppression of activity in the cerebral cortex, particularly the prefrontal cortex (PFC) (Ramey & Regier, 2018; George & Koob, 2017). The disinhibition and impaired judgment seen in intoxication are direct consequences of reduced frontal lobe function, which normally serves to regulate impulses and social behavior (Nahas-Vigon, 2025; Fingerhood, 2020).

### Functional Connectivity and Network Effects

Modern neuroscience conceptualizes brain function in terms of large-scale networks rather than isolated regions. While the provided sources do not include fMRI studies on SHA intoxication, they do discuss the use of such techniques in other contexts, allowing for an informed extrapolation (Jain, 2010). SHA intoxication likely disrupts the functional connectivity both within and between major brain networks. For example, the Default Mode Network (DMN), active during restful introspection, and the Salience Network, involved in detecting and orienting to important stimuli, are likely altered. The cognitive fogginess and reduced awareness of the environment during intoxication may reflect a decoupling of these networks. The disinhibitory effects could be understood as a breakdown in the top-down control exerted by the Executive Control Network (centered in the PFC) over limbic, emotion-driven circuits. This network-level perspective helps to explain how a single pharmacological mechanism—GABA potentiation—can produce such a wide array of cognitive, emotional, and behavioral symptoms.

### Neuroimaging Findings in Clinical Practice

In a clinical context, neuroimaging plays a crucial role in the evaluation of a patient presenting with altered mental status, a common feature of severe SHA intoxication (Misulis & Murray, 2017). Structural imaging techniques like computed tomography (CT) or magnetic resonance imaging (MRI) are essential for differential diagnosis (Chouliaras et al., 2015). They are used to rule out organic causes of altered consciousness that can mimic or be complicated by intoxication, such as traumatic brain injury, stroke, intracranial hemorrhage, or brain tumors (Dodd, 2007; Kerchner & Rosenbloom, 2014; Llauradó Sanz et al., 2015).

While structural imaging is typically normal in uncomplicated SHA intoxication, functional neuroimaging techniques offer a potential window into the underlying neurobiology. Positron Emission Tomography (PET), for instance, has been used extensively in schizophrenia research to quantify dopamine receptor density and occupancy by antipsychotic drugs (Volkow & Wolf, 1991; b'Volkow & b'Wolf, 1991). This same methodology could be applied to SHA intoxication to measure the in-vivo occupancy of benzodiazepine binding sites on the GABA-A receptor at different plasma drug concentrations. Such studies would be invaluable for understanding the relationship between receptor-level effects and clinical symptoms, exploring individual differences in receptor sensitivity, and developing drugs with more targeted profiles (Volkow & Wolf, 1991). Functional MRI (fMRI) could similarly be used to map the specific patterns of brain activation and deactivation associated with intoxication and to investigate the drug's impact on functional connectivity between the brain networks discussed above (Jain, 2010).

## Developmental Neurobiology

The neurobiological effects and clinical presentation of Sedative, Hypnotic, or Anxiolytic Intoxication are profoundly influenced by the developmental stage of the individual. The brain undergoes significant structural and functional changes from infancy through adolescence and into old age, creating periods of differential vulnerability to the effects of these substances. Both the developing brain of an adolescent and the aging brain of a geriatric patient exhibit unique sensitivities that alter the risk and manifestation of intoxication (Dubovický, 2010; Kumagai & Iseki, 2012).

### Vulnerability in Adolescence

Adolescence is a critical period of neurodevelopment characterized by significant synaptic pruning, myelination, and maturation of neurotransmitter systems, particularly within the prefrontal cortex (PFC) (Quartini et al., 2018; Sommer & Arango, 2017). The PFC, responsible for executive functions such as impulse control, decision-making, and risk assessment, is one of the last brain regions to fully mature, a process that continues into the early twenties (Heekerens et al., 2023). This developmental lag creates a neurobiological imbalance where the more mature, subcortical limbic systems that drive reward-seeking and emotional responses are not yet fully regulated by the "top-down" control of the PFC (George & Koob, 2017).

This inherent imbalance makes adolescents particularly vulnerable to the disinhibiting effects of SHAs (Batta & Farid, 2011). By suppressing PFC function, these drugs can exacerbate an adolescent's natural tendency toward impulsivity and risk-taking behavior, contributing to a higher likelihood of engaging in hazardous activities while intoxicated (Daley & Douaihy, 2019; Smith et al., 2010). Furthermore, exposure to addictive substances during this sensitive neurodevelopmental window can interfere with normal brain maturation processes, potentially leading to long-term alterations in neural circuits that increase the risk for developing a substance use disorder later in life (Quartini et al., 2018; Batta & Farid, 2011). The high prevalence of comorbid psychiatric conditions like depression, anxiety, and ADHD in adolescence can further complicate this picture, as individuals may begin using SHAs to self-medicate symptoms, initiating a dangerous cycle of use and dependence (DeMilio, 1989; Winters & Ingwalson, 2022).

### Increased Sensitivity in the Geriatric Population

At the other end of the lifespan, older adults exhibit heightened sensitivity to the effects of SHAs, placing them at significant risk for adverse outcomes during intoxication (Kumagai & Iseki, 2012; Unknown, 2010). This increased vulnerability stems from both pharmacokinetic and pharmacodynamic changes associated with aging. Pharmacokinetically, age-related declines in hepatic metabolism and renal excretion lead to slower drug clearance, resulting in higher plasma concentrations and a prolonged half-life for a given dose (Kumagai & Iseki, 2012). This means that standard adult doses can easily become toxic in an elderly individual, leading to more profound and prolonged intoxication (Marvanová, 2016).

Pharmacodynamically, the aging brain may have altered sensitivity to the effects of these drugs. Changes in neurotransmitter systems and receptor densities can amplify the impact of SHAs on the CNS (Kumagai & Iseki, 2012). Consequently, older adults are more susceptible to the hallmark adverse effects of intoxication, including excessive sedation, cognitive impairment (memory loss, confusion), and psychomotor dysfunction (unsteady gait, poor coordination) (Unknown, 2010; Elhassan et al., 2018). These effects dramatically increase the risk of falls and subsequent fractures, a major cause of morbidity and mortality in this population (Das & Joseph, 2005; Elhassan et al., 2018).

Furthermore, SHA intoxication is a major precipitant of delirium in older adults (Harding, 2005; Llauradó Sanz et al., 2015). Delirium, an acute confusional state characterized by fluctuating attention and cognition, can be difficult to distinguish from underlying dementia but represents an acute medical emergency (Todd & Teale, 2017; Schildkrout, 2014). The delirogenic potential of benzodiazepines and other sedatives is particularly high in individuals with pre-existing cognitive impairment or dementia (Hock et al., 2000; Gani, 2016). Therefore, the use of these drugs in the geriatric population requires extreme caution, with an emphasis on using the lowest effective dose for the shortest possible duration to mitigate the substantial risks of severe intoxication and its complications (Pretl, 2019; Nakamura & Inoue, 2015).

## Treatment Mechanisms

While the primary focus of this chapter is the biology of intoxication, understanding the neurobiological mechanisms of treatment is crucial, particularly concerning the management of severe intoxication and the reversal of its acute effects. The approach to treatment is fundamentally supportive, aimed at maintaining vital functions while the body metabolizes and eliminates the drug (Sarkar et al., 2023). However, in specific cases, targeted pharmacological interventions based on receptor-level neuropharmacology are available.

### Management of Severe Intoxication and Overdose

Severe intoxication with SHAs, particularly barbiturates or co-ingestion with other CNS depressants like alcohol or opioids, can lead to life-threatening respiratory depression, coma, and cardiovascular collapse (Tseng et al., 2020; Nahas-Vigon, 2025). The primary mechanism of this toxicity is the profound, dose-dependent suppression of neuronal activity in the brainstem centers that regulate breathing and cardiovascular function (Horton, 1980; Dahan & Olofsen, 2006). The immediate management of overdose is therefore focused on supportive care, with the foremost priority being the protection of the airway and maintenance of adequate ventilation and circulation (Sarkar et al., 2023; Horton, 1980). This may require endotracheal intubation and mechanical ventilation to prevent hypoxic brain injury secondary to respiratory failure (Horton, 1980; Beed et al., 2013).

### Pharmacological Reversal: The Role of Flumazenil

For intoxication specifically involving benzodiazepines or Z-drugs (e.g., zolpidem), a specific antidote, flumazenil, is available. Flumazenil is a competitive antagonist at the benzodiazepine binding site on the GABA-A receptor (Nishino et al., 2017). It binds to this site with high affinity but has no intrinsic activity of its own; instead, it competitively displaces the benzodiazepine agonist from the receptor, thereby reversing its potentiating effect on GABAergic transmission (Krejcie & Avram, 2011). This rapid reversal of GABAergic enhancement can lead to a dramatic improvement in the level of consciousness and respiratory function in patients with pure benzodiazepine overdose (Sarkar et al., 2023).

However, the use of flumazenil is not without risks and is contraindicated in certain situations. In patients with chronic benzodiazepine dependence, the abrupt reversal of GABAergic tone by flumazenil can unmask the underlying neuroadaptive state of CNS hyperexcitability, precipitating an acute and severe withdrawal syndrome, including status epilepticus (Tseng et al., 2020; Kofke et al., 1997). Similarly, in cases of mixed overdose involving pro-convulsant drugs like tricyclic antidepressants, flumazenil can lower the seizure threshold and precipitate seizures (Coleman, 2004). For these reasons, its use is generally reserved for cases of pure benzodiazepine overdose in non-dependent individuals or for reversing iatrogenic sedation in a controlled medical setting (Sarkar et al., 2023). It is ineffective for intoxication caused by barbiturates or alcohol, which bind to different sites on the GABA-A receptor complex (Tseng et al., 2020).

### Management of Paradoxical Reactions

Paradoxical reactions to SHAs, such as agitation, aggression, or disinhibition, present a different treatment challenge (倉田明子 et al., 2011). These behaviors are thought to result from the disinhibition of cortical control over underlying aggressive or impulsive drives, an effect mediated by the suppression of frontal lobe function (Breggin, 1998; Swann, 2012). The management of such agitation involves providing a low-stimulation environment and, if necessary, the judicious use of sedative medications (Sarkar et al., 2023). Ironically, benzodiazepines themselves are sometimes used for this purpose, although this carries the risk of worsening the disinhibition (Adès & Lejoyeux, 1993). In cases of severe agitation or psychosis, antipsychotic medications such as haloperidol may be required to restore behavioral control (Sarkar et al., 2023; Garza-Treviño, 1988). The mechanism here involves blockade of dopamine D2 receptors, which counteracts the downstream effects of limbic disinhibition (Lambert et al., 2003). These interventions highlight how an understanding of the underlying neurobiology—be it GABAergic over-activity or dopaminergic disinhibition—guides the rational selection of therapeutic agents.

## Future Directions

While the fundamental GABAergic mechanisms of common sedative, hypnotic, and anxiolytic drugs are well-established, significant questions remain, and the field continues to evolve. Future research will likely focus on refining our understanding of the network-level effects of these drugs, identifying biomarkers for susceptibility to adverse effects, and developing novel therapeutic agents with improved safety and efficacy profiles.

One of the most pressing needs is for human neuroimaging studies that directly investigate the acute effects of SHA intoxication. While PET studies have been invaluable for mapping receptor occupancy of antipsychotics in schizophrenia (Volkow & Wolf, 1991; b'Volkow & b'Wolf, 1991), similar research is needed to correlate GABA-A receptor occupancy with specific clinical effects of intoxication, such as cognitive impairment, ataxia, and amnesia. This would help clarify dose-response relationships in vivo and explain inter-individual variability (Volkow & Wolf, 1991). Furthermore, advanced fMRI techniques could elucidate how these drugs disrupt the functional connectivity of large-scale brain networks, providing a more integrated understanding of how enhanced GABAergic inhibition translates into the complex behavioral and cognitive syndrome of intoxication (Jain, 2010).

Another critical area for future investigation is the genetic and molecular basis of individual differences in drug response. Research should aim to identify specific genetic polymorphisms in GABA-A receptor subunits or metabolic enzymes that predict sensitivity to intoxication or risk for adverse reactions, including paradoxical agitation and dependence (Petit & Sansone, 2011). A deeper understanding of these factors could pave the way for personalized medicine, allowing clinicians to select agents and doses that are optimized for an individual's genetic profile, thereby minimizing risk (Nelson & Chouinard, 1999).

The development of novel therapeutic agents remains a high priority. The limitations of traditional benzodiazepines and barbiturates—including cognitive side effects, dependence liability, and risk of respiratory depression—have spurred the search for safer alternatives (Ohta, 1996; Kales, 1990). The emergence of drugs with novel mechanisms, such as the selective melatonin receptor agonists and orexin receptor antagonists, represents a significant step forward (Nakamura & Inoue, 2015; Kallweit et al., 2023; Neubauer et al., 2008). These agents offer the potential to modulate the sleep-wake cycle more physiologically, without causing global CNS depression (Kallweit et al., 2023). Future research should continue to explore other non-GABAergic targets for the treatment of insomnia and anxiety, aiming to dissociate therapeutic effects from undesirable sedation and cognitive impairment.

Finally, a better understanding of the long-term neuroplastic changes induced by chronic SHA use is essential. While the "seesaw" model provides a powerful conceptual framework for tolerance and withdrawal (Goldstein, 2001), the specific molecular and cellular adaptations (e.g., changes in receptor expression, synaptic strength, and gene expression) need to be further characterized (Antonio & Alfredo, 2012). Elucidating these long-term changes is not only crucial for understanding the pathophysiology of addiction but also for developing interventions that can reverse these adaptations and aid in the recovery from substance use disorders.

## Conclusion

Sedative, Hypnotic, or Anxiolytic Intoxication is a complex neuropsychiatric syndrome arising from the dose-dependent depression of the central nervous system. The neurobiological foundation of this state, for classic agents like benzodiazepines and barbiturates, is the potentiation of the brain's primary inhibitory neurotransmitter, GABA, at the GABA-A receptor (Tseng et al., 2020; Nishino et al., 2017). This fundamental mechanism triggers a cascade of inhibitory effects across a distributed network of brain regions, including the brainstem arousal centers, limbic emotional circuits, cerebellum, and cerebral cortex, which collectively produce the characteristic symptoms of sedation, anxiolysis, motor incoordination, and cognitive impairment (Sarkar et al., 2023; Nahas-Vigon, 2025).

The clinical presentation of intoxication is remarkably heterogeneous, shaped by the specific pharmacologic properties of the drug, the dose administered, and a host of individual factors. Genetic variations in metabolic enzymes and receptor subunits contribute to differences in susceptibility and the severity of intoxication (Nelson & Chouinard, 1999). Developmental stage is also a critical modulator, with adolescents and the elderly representing populations with unique vulnerabilities to disinhibition and adverse cognitive and motor effects, respectively (Kumagai & Iseki, 2012; Batta & Farid, 2011). Furthermore, the expression of intoxication can be complicated by paradoxical reactions such as agitation and aggression, and is often modified by the presence of comorbid psychiatric or medical conditions (倉田明子 et al., 2011; Buckley, 2007).

The brain's response to chronic exposure to these agents involves profound neuroplastic and compensatory changes, as described by the oppositional model of tolerance, leading to dependence and a state of CNS hyperexcitability that manifests as a withdrawal syndrome upon cessation of the drug (Goldstein, 2001; Fava & Cosci, 2019). Understanding these adaptive mechanisms is key to the rational management of both dependence and withdrawal. While our knowledge of the GABAergic system is extensive, the future of this field lies in elucidating the network-level consequences of intoxication, exploring the genetic basis of individual vulnerability, and developing novel therapeutics that target sleep-wake and anxiety-regulating systems with greater specificity and safety.


## References

1. Abdelsayed, S., Acevedo, R., & Clemow, L. (2017). Is sleep deprivation associated with behavioral changes in children and adolescents?. Evidence-Based Practice. https://doi.org/10.1097/01.ebp.0000541629.93211.cb
2. Abdo, C. H. N. (2017). Sexualidade e doenças reumáticas. Revista Paulista de Reumatologia. https://doi.org/10.46833/reumatologiasp.2017.16.3.6-12
3. Abe, Y., & Germai, A. (2012). Insomnia and Its Correlates: Current Concepts, Epidemiology, Pathophysiology and Future Remarks. InTech eBooks. https://doi.org/10.5772/36102
4. Abhilash, K. P., Jha, A., Bandhyopadhyay, R., & Victor, P. (2014). Hypoglycemia - A rare complication of carbamazepine overdose. Indian Journal of Pharmacology. https://doi.org/10.4103/0253-7613.144941
5. Abi‐Jaoude, E., Stall, N. M., & Rochon, P. A. (2018). Psychotropic drugs for the behavioural and psychological symptoms of dementia: no free ride. Canadian Medical Association Journal. https://doi.org/10.1503/cmaj.181486
6. Adams, B., & Bromley, B. (1998). Loss and grief therapy. https://doi.org/10.1007/978-1-349-26634-0_10
7. Adams, C. E., Wilson, P., Gilbody, S., Bagnall, A., & Lewis, R. (2000). Drug treatments for schizophrenia. Quality in Health Care. https://doi.org/10.1136/qhc.9.1.73
8. Adler, G. (2006). Diagnostik der Demenz. Notfall & Hausarztmedizin (Notfallmedizin). https://doi.org/10.1055/s-2006-959110
9. Afonso, H., Froes, V., Varela, I., Esteves, F., Carneiro, M., Esteves, S. C., & Lima, G. M. D. (2019). 11 - TRANSDIAGNOSTIC THERAPY IN THE TREATMENT OF EATING DISORDERS. https://doi.org/10.26226/morressier.5d1a038957558b317a13fe8b
10. Agarwal, V., Sitholey, P., & Srivastava, C. (2019). Clinical practice guidelines for the management of dissociative disorders in children and adolescents. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_493_18
11. Aggelakis, E. (2018). Neuropsychological assessment for the differential diagnosis of Attention Deficit / Hyperactivity Disorder (AD/HD). DOAJ (DOAJ: Directory of Open Access Journals). https://doi.org/10.26386/obrela.v1i0.21
12. Akwa, Y., Allain, H., Lacomblez, L., Lieury, A., & Bentué‐Ferrer, D. (2007). Impaired cognition and attention in adults: pharmacological management strategies. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/nedt.2007.3.1.103
13. Al-Tajali, A. N. A. (2015). Low-Dose Clozapine for an Adolescent with TBI-Related Fregoli Delusions. Journal of Psychiatry. https://doi.org/10.4172/2378-5756.1000306
14. Alam, N., & Choudhary, K. (2023). Neurochemical Effects of Methylphenidate and Modafinil in Ameliorating Stress-Induced Cognitive Deficits. ACS Pharmacology & Translational Science. https://doi.org/10.1021/acsptsci.3c00077
15. Alfonso, I., Papazian, Ó., Aicardi, J., & Jeffries, H. E. (1995). A Simple Maneuver to Provoke Benign Neonatal Sleep Myoclonus. PEDIATRICS. https://doi.org/10.1542/peds.96.6.1161
16. Alvarez, C. M. (2016). Efectos de la estimulación multisensorial dentro de una sala oscura en el tratamiento del equilibrio en niños de 5 a 7 años con discapacidad intelectual.
17. Amorim, M. J., Maurício, J., & Brandão, D. (2019). WHEN THE DISEASE ARISES FROM THE TREATMENT: CORTICOSTEROID-INDUCED PSYCHOSIS A CASE REPORT AND BRIEF LITERATURE REVIEW. https://doi.org/10.26226/morressier.5d1a037b57558b317a140b63
18. Anderson, T., Heitger, M., & Macleod, A. D. (2006). Concussion and mild head injury. Practical Neurology. https://doi.org/10.1136/jnnp.2006.106583
19. Andrade, C. (2004). Antidepressant-Withdrawal Mania. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v65n0716
20. Andrade, C. (2012). Drugs That Escape Hepatic Metabolism. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.12f07726
21. Anisman, H., Merali, Z., Poulter, M. O., & Hayley, S. (2005). Cytokines as a Precipitant of Depressive Illness: Animal and Human Studies. Current Pharmaceutical Design. https://doi.org/10.2174/1381612053381701
22. Ansari, I., Jabbar, Q., & Asim, S. A. (2018). Depression and its treatment - a mini review. Journal of Psychology & Clinical Psychiatry. https://doi.org/10.15406/jpcpy.2018.09.00587
23. Antonio, E., & Alfredo, E. (2012). Cocaine Addiction: Changes in Excitatory and Inhibitory Neurotransmission. InTech eBooks. https://doi.org/10.5772/34410
24. Anuzyte, J. S., Rutkauskaitė, G., & Mameniškienė, R. (2018). Transient epileptic amnesia. Neurologijos seminarai. https://doi.org/10.29014/ns.2018.26
25. Arango, C., Kirkpatrick, B., & Buchanan, R. W. (2000). Neurological Signs and the Heterogeneity of Schizophrenia. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.157.4.560
26. Araújo, R. C. B., Gomes, R. M., & Barbosa, M. U. F. (2017). A IMPORTÂNCIA DO BOBATH EM PACIENTES COM PARALISIA CEREBRAL.
27. Archila, R. (2000). Epilepsia y trastornos del aprendizaje. Revista de Neurología. https://doi.org/10.33588/rn.3104.2000284
28. Ardila, A., Niño, C. R., Pulido, E., Rivera, D. B., & Vanegas, C. J. (1993). Episodic Psychic Symptoms in the General Population. Epilepsia. https://doi.org/10.1111/j.1528-1157.1993.tb02385.x
29. Arenson, C., Busby‐Whitehead, J., Brummel‐Smith, K., O’Brien, J. G., Palmer, M. H., & Reichel, W. (2010). Evaluation and Management of Dementia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511575952.017
30. Arrowsmith, J. E. (2010). Central nervous system. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199209101.003.05
31. Arteaga, T. L., Amo, C., González, C. S., & Sánchez, D. H. (2013). Nonconvulsive status epilepticus and psychotic symptoms: case report.. PubMed. https://doi.org/10.1708/1292.14295
32. As, B., On, C., & NIu, R. (2014). [Bipolar depression in the clinic of schizophrenia].. PubMed.
33. Asadi, S. (2023). The Role of Bio- Psychological Factors in Sleep Anxiety and Hypomania Disorder. https://doi.org/10.31579/2835-2882/016
34. Autor, S. (2002). CÁPSULAS PARA LA VIDA.- ANSIEDAD. Gaceta UNAM (2000-2009).
35. Axelson, O. (1996). Where do we go in occupational neuroepidemiology?. Scandinavian Journal of Work Environment & Health. https://doi.org/10.5271/sjweh.114
36. Ayala, L., Gómez‐Revuelta, M., Requena, C. M., Acilu, E. S. D. A. G. D., Olivares, O. P., Ruíz, M. J., Morales, N. N., Martin, M., Zufiaurre, M. L., Hernández, B., Itoiz, A. A., Peña, M., & González‐Pinto, A. (2017). Clozapine: Since the very beginning?. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.1402
37. b'Volkow, N. D., & b'Wolf, A. P. (1991). b'THE USE OF POSITRON EMISSION TOMOGRAPHY IN IDENTIFYING AND QUANTIFYING RECEPTORS INVOLVED IN SCHIZOPHRENIA.'.
38. Bachmann, C. (2015). Padma 28 bei Restless-Legs-Syndrom: Fallberichte wecken Hoffnungen auf Wirksamkeit. Schweizerische Zeitschrift für Ganzheitsmedizin / Swiss Journal of Integrative Medicine. https://doi.org/10.1159/000434622
39. Bains, N., Abdijadid, S., & Miller, J. (2021). Major Depressive Disorder (Nursing).
40. Balvir, K. S., Dhanvij, B., Telrandhe, S., & Wajgi, R. D. (2021). A Case Report on Management of Subdural Hematoma. NVEO - NATURAL VOLATILES & ESSENTIAL OILS Journal | NVEO.
41. Bano, S., Das, S., Mazumder, A., Das, S., & Aman, S. (2015). The Landau Kleffner Syndrome.
42. Bansal, V., Ruland, S., & Aiyagari, V. (2014). DISORDERS OF CONSCIOUSNESS. CRC Press eBooks. https://doi.org/10.1201/b16337-7
43. Barbeau, G. (2006). La sexualité de la personne âgée et les médicaments. Santé mentale au Québec. https://doi.org/10.7202/030083ar
44. Barbosa, G. (2017). Preservação das funções executivas em ratos expostos ao Status Epilepticus neonatal.
45. Barbosa, M. O. S., Silva, F. L. C., Castro, J. D. O., Marino, L. D. B., Silva, V. D. S., Pinho, R. C., & Bonfim, Y. C. (2018). PROCESSO DE ENFERMAGEM EM PACIENTE COM ESQUIZOFRENIA HEBEFRÊNICA: UM RELATO DE CASO. 13º Congresso Internacional Rede Unida.
46. Batinić, B., Duišin, D., & Vukosavljevic-Gvozden, T. (2017). Neurobiological bases for impulsive and compulsive behaviour: Implications for pharmacological and psychological interventions. Engrami. https://doi.org/10.5937/engrami1701017b
47. Batta, A., & Farid, B. (2011). Addiction in Adolescents ---- A Current Trend.
48. Becker, H. C., & Redmond, N. (2002). Role of Glutamate in Alcohol Withdrawal Kindling. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_25
49. Becker, S. P., & Barkley, R. A. (2018). Sluggish cognitive tempo. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198739258.003.0015
50. Beed, M., Sherman, R. A., & Mahajan, R. (2013). Neurology. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696277.003.0005
51. Bellamkonda, P., Mansou, G., Tantoush, H., & Abuzaid, A. (2014). Marijuana Induced Transient Global Amnesia.
52. Benatmane, M., Benhabiles, S., Machane, R., Hammal, K., & Sinaceur, S. (2014). La dépression peut mimer n’importe quelle maladie : à propos d’un cas clinique. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2014.09.241
53. Beni, F. (2019). Addiction and Trauma Re-examined through the lens of Complexity Theory. Psychology and Behavioral Science International Journal. https://doi.org/10.19080/pbsij.2019.13.555853
54. Beninger, R. J. (2018). Life's rewards. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198824091.001.0001
55. Berk, M., Post, R. M., Ratheesh, A., Gliddon, E., Singh, A., Vieta, E., Carvalho, A. F., Ashton, M. M., Berk, L., Cotton, S., McGorry, P. D., Fernandes, B. S., Yatham, L. N., & Dodd, S. (2017). Staging in bipolar disorder: from theoretical framework to clinical utility. World Psychiatry. https://doi.org/10.1002/wps.20441
56. Bertodo, T. D. S., Gross, M. S., & Maldaner, E. B. (2018). TRANSTORNOS BIPOLAR E DEPRESSIVO: UMA REVISÃO DOS ASPECTOS CONCEITUAIS.
57. Besag, F., Gobbi, G., Aldenkamp, A. P., Caplan, R., Dunn, D. W., & Sillanpää, M. (2016). Psychiatric and Behavioural Disorders in Children with Epilepsy (ILAE Task Force Report): Subtle behavioural and cognitive manifestations of epilepsy. Epileptic Disorders. https://doi.org/10.1684/epd.2016.0816
58. Beszczyńska, B. (2007). [Molecular basis of stress-evoked psychiatric disturbances].. PubMed.
59. Bischoff, P., & Rundshagen, I. (2011). Awareness Under General Anesthesia. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2011.0001
60. Biswas, D., Jamwal, A. S., Beniwal, A., Brar, T., & Saran, B. (2023). Treatment in obsessive–compulsive disorder. Santosh University Journal of Health Sciences. https://doi.org/10.4103/sujhs.sujhs_62_23
61. Bitnun, A., & Richardson, S. E. (2015). Childhood Encephalitis in Canada in 2015. Canadian Journal of Infectious Diseases and Medical Microbiology. https://doi.org/10.1155/2015/947602
62. Bittencourt, L., Silva, R. S., Santos, R. F., Pires, M. L. N., & Mello, M. T. D. (2005). Sonolência excessiva. Brazilian Journal of Psychiatry. https://doi.org/10.1590/s1516-44462005000500004
63. Blanc, F., & Verny, M. (2017). Prodromal stage of disease (dementia) with Lewy bodies, how to diagnose in practice?. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2017.0675
64. Blanco, C., & Bernardi, S. (2014). Gambling Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg62
65. Borsook, D., Aasted, C. M., Burstein, R., & Becerra, L. (2013). Migraine Mistakes. The Neuroscientist. https://doi.org/10.1177/1073858413503711
66. Boughton, B. J. (1991). Hepatic and portal vein-thrombosis.. BMJ. https://doi.org/10.1136/bmj.302.6770.192
67. Bourin, M., David, D. J., & Dhonnchadha, B. À. N. (2002). Sedation: a non-specific phenomenon -. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology.
68. Bradic, L., Lokmić-Pekić, I., & Dzevad, B. (2018). Psychiatric comorbidity in patients with posttraumatic stress disorder and enduring personality change after catastrophic experience. https://doi.org/10.26226/morressier.5b68175cb56e9b005965c22b
69. Brang, D. (2010). Synesthesia. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0971
70. Breggin, P. R. (1998). ANALYSIS OF ADVERSE BEHAVIORAL EFFECTS OF BENZODIAZEPINES WITH A DISCUSSION ON DRAWING SCIENTIFIC CONCLUSIONS FROM THE FDA'S SPONTANEOUS REPORTING SYS TEM. The Journal of mind and behavior.
71. Brody, D. L. (2019). How Do You Make the Diagnosis of Concussion?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190054793.003.0003
72. Brody, D. L. (2019). Mood Instability and Irritability. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190054793.003.0010
73. Broers, D. (2010). Patiënten met ongewone extractiewensen 2. Wilsonbekwaamheid en psychopathologische oorzaken. Nederlands Tijdschrift voor Tandheelkunde. https://doi.org/10.5177/ntvt.2010.11.10121
74. Brown, S. L. (2006). Deterioration. Epilepsia. https://doi.org/10.1111/j.1528-1167.2006.00682.x
75. Buckley, P. (2007). Dual Diagnosis of Substance Abuse and Severe Mental Illness: The Scope of the Problem. Journal of Dual Diagnosis. https://doi.org/10.1300/j374v03n02_07
76. Burkart, J., Jong, M. C., Ilenkyo, L., Verwer, C., Weber, S., Keller, T., & Klement, P. (2017). P172 Results of a randomised controlled trial with a homeopathic complex medicinal product in children with sleep disorders and restlessness. https://doi.org/10.1136/archdischild-2017-313273.260
77. Burke, A., Yaari, R., Tariot, P. N., Dougherty, J., Fleisher, A., & Brand, H. (2012). The Shadow People. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.12alz01398
78. Burkhart, P. W. M. K. K. (2014). Drugs Highly Associated with Infusion Reactions Reported using Two Different Data-mining Methodologies. Journal of Blood Disorders & Transfusion. https://doi.org/10.4172/2155-9864.1000195
79. Burnett, M. S. (2015). Hyperkinetic Movement Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190244927.003.0027
80. Cadoret, R. J., & Winokur, G. (1972). Genetic Principles in the Classification of Affective Illnesses. International Journal of Mental Health. https://doi.org/10.1080/00207411.1972.11448572
81. Calvani, M., Anania, C., Cuomo, B., D’Auria, E., Decimo, F., Indirli, G. C., Mastrorilli, V., Santoro, A., Sartorio, M. U. A., & Veronelli, E. (2020). Summation anaphylaxis: A challenging diagnosis. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.13347
82. Canapathy, M., Kurushev, J., Chitra, F., & Dash, M. (2019). Impact of Sensory Deprivation on Health Outcome. Acta Scientific Paediatrics. https://doi.org/10.31080/aspe.2019.02.0165
83. Cardeña, E. (2018). Derangement of the senses or alternate epistemological pathways? Altered consciousness and enhanced functioning.. Psychology of Consciousness Theory Research and Practice. https://doi.org/10.1037/cns0000175
84. Carlson, G. A., & Pataki, C. (2016). Disruptive Mood Dysregulation Disorder Among Children and Adolescents. FOCUS The Journal of Lifelong Learning in Psychiatry. https://doi.org/10.1176/appi.focus.20150039
85. Carolina, P. J., & William, B. (2013). Neuropsicología en epilepsia. Revista Médica Clínica Las Condes. https://doi.org/10.1016/s0716-8640(13)70253-0
86. Carrera, M. A. V., Correa, S. M. V., Prado, M. M. C., & Granados, K. P. M. (2019). Manejo de intoxicación por opioides. RECIMUNDO. https://doi.org/10.26820/recimundo/3.(4).diciembre.2019.494-510
87. Carson-DeWitt, R. (2000). Treatments for Parkinson's disease.. PubMed.
88. Carvajal, C. (2004). Poor response to treatment: beyond medication. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2004.6.1/ccarvajal
89. Carvajal, C. (2004). Poor response to treatment: beyond medication.. PubMed.
90. Casanova, Y. C., Torres, M. N., Ramírez, M. D. L., Ferrer, A. B., Calvo, R. N., & Ramos, I. J. (2021). Plan de cuidados de enfermería para paciente con deterioro de la movilidad.. Revista Sanitaria de Investigación.
91. CASEY, P., & Bailey, S. (2011). Adjustment disorders: the state of the art. World Psychiatry. https://doi.org/10.1002/j.2051-5545.2011.tb00003.x
92. Cha, Y., Baloh, R. W., Cho, C., Magnusson, M., Song, J., Strupp, M., Wuyts, F. L., & Staab, J. P. (2020). Mal de débarquement syndrome diagnostic criteria: Consensus document of the Classification Committee of the Bárány Society. Journal of Vestibular Research. https://doi.org/10.3233/ves-200714
93. Chang, A. N., Kiyokawa, M., & Grysman, N. (2025). Cocaine Induced Postictal Psychosis: a Rare Cause of Antipsychotic Resistant Psychosis. Hawai‘i Journal of Health &amp Social Welfare. https://doi.org/10.62547/nmiq4624
94. Chang, Y., Han, I.-W., Na, H. R., & Kim, S.-Y. (2010). Encephalitis Lethargica With Catatonia. Journal of the Korean Neurological Association.
95. Charles, A. (2012). Migraine is not primarily a vascular disorder. Cephalalgia. https://doi.org/10.1177/0333102412441717
96. Chatterton, C., & Jones, G. (2013). Interpretative aspects of toxicological results. https://doi.org/10.4155/ebo.13.54
97. Chaudhry, H., Arshad, N., Niaz, S., Cheema, F., Iqbal, M., & Mufti, K. (2005). Fifteen-year follow-up of conversion disorder. International Psychiatry. https://doi.org/10.1192/s1749367600007517
98. Cheung, K., Patch, K., Earp, B. D., & Yaden, D. B. (2023). Psychedelics, Meaningfulness, and the “Proper Scope” of Medicine: Continuing the Conversation. Cambridge Quarterly of Healthcare Ethics. https://doi.org/10.1017/s0963180123000270
99. Chicharro-Ciuffardi, A., González-Silva, M., Marinis-Palombo, A. D., & Gabler-Santalices, G. (2012). Psychiatric disorders secondary to nonconvulsive status epilepticus of frontal origin. Two clinical case reports.. PubMed.
100. Chiliza, B., & Vythilingum, B. (2011). Consultation liaison psychiatry in Africa – essential service or unaffordable luxury?. African Journal of Psychiatry. https://doi.org/10.4314/ajpsy.v14i4.1
101. Chiu, Y. C. (2015). Behavioral-Variant Frontotemporal Neurocognitive Disorder Presenting as Insomnia. Journal of Psychiatry. https://doi.org/10.4172/2378-5756.1000298
102. Choo, K.-Q., Wl, L., How, C., & Ng, B. (2015). Hoarding in Singapore. Singapore Medical Journal. https://doi.org/10.11622/smedj.2015131
103. Chou, R., Norris, S. L., Carson, S., & Chan, B. (2007). Drug Class Review: Drugs for Neuropathic Pain: Final Report [Internet].
104. Chouliaras, L., Topiwala, A., Cristescu, T., & Ebmeier, K. P. (2015). Establishing the cause of memory loss in older people.. PubMed.
105. Chow, C. K., & Koren, G. (2015). Sedating drugs and breastfeeding.. PubMed.
106. Chow, T. W., Pollock, B. G., & Milgram, N. W. (2007). Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease.. PubMed.
107. Chummun, H., Tilley, V., & Ibe, J. (2010). 3,4-methylenedioxyamfetamine (ecstasy) use reduces cognition.. British Journal of Nursing.
108. Chumpitazi, C. E. (2018). Minor Adverse Events. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190659110.003.0022
109. Cianchetti, C., Pruna, D., & Ledda, M. (2013). Epileptic seizures and headache/migraine: A review of types of association and terminology. Seizure. https://doi.org/10.1016/j.seizure.2013.05.017
110. Ciraulo, D. M., & Ciraulo, D. A. (2008). Benzodiazepines <i>Misuse, Abuse, and Dependence</i>. https://doi.org/10.1093/oso/9780195300550.003.0019
111. Ciszowski, K., & Mietka-Ciszowska, A. (2013). [Rare consciousness disturbances in toxicological practice: akinetic mutism, somnambulism, locked-in syndrome, and psychogenic coma].. PubMed.
112. Ciszowski, K., & Mietka-Ciszowska, A. (2013). [Toxicant-induced and drug-induced coma neurotoxicological issues of general anesthesia].. PubMed.
113. Clay, S., Allen, J. V., & Parran, T. (2008). A Review of Addiction. Postgraduate Medicine. https://doi.org/10.3810/pgm.2008.07.1802
114. Coleman, J. J. (2004). Drug-induced seizures. Adverse Drug Reaction Bulletin. https://doi.org/10.1097/00012995-200408000-00001
115. Colán, T. C., Gálvez, G. A., & Zevallos, D. C. (2013). Síntomas psiquiátricos e insulinoma: reporte de caso Psychiatric symptoms and insulinoma: a case report.
116. Consroe, P., & Snider, S. R. (2019). Therapeutic Potential of Cannabinoids in Neurological Disorders * , †. Chapman and Hall/CRC eBooks. https://doi.org/10.1201/9780429260667-2
117. Cooper, L., Copeland, S., Dailey, S., Downey, D., Petersen, M. C., Stimson, C., & Dyke, D. C. V. (2008). Feeding and swallowing dysfunction in genetic syndromes. Developmental Disabilities Research Reviews. https://doi.org/10.1002/ddrr.19
118. Coronado, L. M. Q., Florez, D. A. C., & Tarazona, M. C. L. (2017). Prevalencia depresión en estudiantes universitarios Bucaramanga 2017.
119. Correll, C. U., Yu, X., Xiang, Y., Kane, J. M., & Masand, P. S. (2017). Biological treatment of Acute Agitation Or Aggression with Schizophrenia Or Bipolar Disorder in the Inpatient Setting. Annals of Clinical Psychiatry. https://doi.org/10.1177/104012371702900203
120. Costanzo, R. M., DiNardo, L. J., Reiter, E. R., & Doty, R. L. (2003). Head Injury and Taste. CRC Press eBooks. https://doi.org/10.1201/9780203911457-50
121. Couto, F. S. D., & Mendonça, A. D. (2010). Sintomas psiquiátricos e comportamentais da demência. Revista Portuguesa de Clínica Geral. https://doi.org/10.32385/rpmgf.v26i1.10713
122. Cristina, L., Făget, D., Chiriță, V., Chiriță, R., & Manea, M. (2019). "Alternative therapies and management of dementia in Alzheimer's disease". Bulletin of Integrative Psychiatry. https://doi.org/10.36219/bpi.2019.04.07
123. Cristofor, A.-C., Popa, T., Crețeanu, A., Rusu, G., & Mititelu-Tarțău, L. (2016). Farmacoterapia depresiei la pacientul vârstnic. Farmacist ro.
124. Cruz, S. L., & López, C. B. (2003). Fármacos que producen dependencia física y adicción. Avance y perspectiva.
125. Cuché, H. (2005). [Which signs in a depressed patient could indicate a manic transformation?].. PubMed.
126. Cummings, J. L., Arciniegas, D. B., Brooks, B. R., Herndon, R. M., Lauterbach, E. C., Pioro, E. P., Robinson, R. G., Scharre, D. W., Schiffer, R. B., & Weintraub, D. (2006). Defining and Diagnosing Involuntary Emotional Expression Disorder. CNS Spectrums. https://doi.org/10.1017/s1092852900026614
127. Dahan, A., & Olofsen, E. (2006). Hypercapnia. Wiley Encyclopedia of Biomedical Engineering. https://doi.org/10.1002/9780471740360.ebs0592
128. Daley, D. C., & Douaihy, A. (2006). Medications in Dual Recovery. https://doi.org/10.1093/oso/9780195311297.003.0006
129. Daley, D. C., & Douaihy, A. (2006). Understanding Mood Disorders: Depression and Bipolar Illness. https://doi.org/10.1093/oso/9780195311297.003.0003
130. Daley, D. C., & Douaihy, A. (2019). Substance-Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0002
131. Dalvi, A., Lyons, K. E., & Pahwa, R. (2012). Secondary dystonia. CRC Press eBooks. https://doi.org/10.3109/9781841848525-20
132. Das, C., & Joseph, S. (2005). Falls in elderly.. PubMed.
133. David, G., Monge, M. P., Arántzazu, D., Fernanda, A., Fernanda, T. M., Gemma, M., & Sandra, D. (2016). Schizophrenia and sexual desinhibition. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.2162
134. David, R., Piano, J., & Robert, P. (2011). [Treatment of behavioral disorders in Alzheimer's disease].. PubMed.
135. Deakin, J., & Lennox, B. (2013). Psychotic symptoms in young people warrant urgent referral.. PubMed.
136. DeJong, R. N. (1969). Memory Loss due to Hippocampal Lesions. Archives of Neurology. https://doi.org/10.1001/archneur.1969.00480100015001
137. Delfino, A., Luengo, V., Zapata, C., Calderón, J., & Tugas, M. G. (2010). [Anesthesia awareness].. PubMed.
138. Delgado, Y. O., Reyes, A. C., & Imas, Y. A. (2012). Trastorno por estrés agudo: Presentación de un caso. Cuadernos de Medicina Forense. https://doi.org/10.4321/s1135-76062012000100004
139. DeLuca, G. C., & Bartleson, J. D. (2010). When and How to Investigate the Patient with Headache. Seminars in Neurology. https://doi.org/10.1055/s-0030-1249221
140. Demey, I., Zimerman, M., Allegri, R., Serrano, C., & Taragano, F. (2004). Neuropsychiatric symptoms of mild cognitive impairment. CRC Press eBooks. https://doi.org/10.3109/9780203492857-7
141. DeMilio, L. (1989). Psychiatric syndromes in adolescent substance abusers. American Journal of Psychiatry. https://doi.org/10.1176/ajp.146.9.1212
142. Derman, E., Whitesman, S., Dreyer, M., Patel, D., Nossel, C., & Schwellnus, M. (2010). Healthy lifestyle interventions in general practice: Part 12: Lifestyle and depression. South African Family Practice. https://doi.org/10.1080/20786204.2010.10873989
143. Desseilles, M., Sterpenich, V., Dang‐Vu, T. T., & Schwartz, S. (2011). REM sleep and emotion regulation. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511921179.044
144. Diamond, G., Senecky, Y., Keren, M., Inbar, D., Shufer, A., & Cohen, H. (2006). PSEUDONEUROLOGICAL SYNDROME IN INSTITUTIONALIZED INFANTS PRIOR TO BONDING AND ADOPTION. Neuropediatrics. https://doi.org/10.1055/s-2006-945637
145. Dias, R. D. S. (2010). Estudo comparativo do fenótipo clínico de mulheres com transtorno afetivo bipolar em fase reprodutiva da vida com e sem piora pré-menstrual do humor. https://doi.org/10.11606/t.5.2010.tde-28052010-101220
146. Dodd, M. L. (2007). BASIC PRINCIPLES OF PSYCHIATRY. CRC Press eBooks. https://doi.org/10.1201/b14430-11
147. Domínguez, L. N., Martin, P. R., Olea, A. M., Martínez, N. B., Sanjosé, G. U., González, M. M., & Tolosa-Delgado, A. (2016). Atypical Psychotic Symptoms in Lafora´s Disease: A Case Report.
148. Drago, F., & Caraci, F. (2020). Faculty Opinions recommendation of Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review.. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. https://doi.org/10.3410/f.733303213.793576054
149. Dubovický, M. (2010). Neurobehavioral manifestations of developmental impairment of the brain. Interdisciplinary Toxicology. https://doi.org/10.2478/v10102-010-0012-4
150. Duletic, N., Mijatovic-Papic, T., Cizmovic, B., & Kusturica, S. (2015). Differential Diagnostic Consideration of the Syndrome of Psychomotor Agitation in Geriatric Population. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)31130-5
151. During, E., & Winkelman, J. W. (2022). Restless Legs Syndrome and Psychiatric Issues. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197574317.003.0019
152. Díaz, C. M., Solá, M. G., & Sánchez, M. T. (2013). Enfermedad de Creutzfeldt-Jacob: [caso clínico].
153. D’cruz, M., Andrade, C., & Rao, T. S. (2020). The Expression of Intimacy and Sexuality in Persons With Dementia. Journal of Psychosexual Health. https://doi.org/10.1177/2631831820972859
154. Ebenezer, I. S. (2015). Affective Disorders 1: Depression. https://doi.org/10.1002/9781118385777.ch6
155. Ebenezer, I. S. (2015). Affective Disorders 2: Bipolar Disorder. https://doi.org/10.1002/9781118385777.ch7
156. Edwards, J. G. (1995). Depression, antidepressants, and accidents. BMJ. https://doi.org/10.1136/bmj.311.7010.887
157. Ehler, E., Kopal, A., Mandysová, P., & Latta, J. (2011). Komplikace ischemické cévní mozkové příhody. Neurologie pro praxi.
158. Eichlerová, A., Ehler, E., Šalandová, J., & Latta, J. (2010). Chronická intoxikace technickým benzinem profesionálního původu. Neurologie pro praxi.
159. Eisenschenk, S., Krop, H., & Devinsky, O. (2014). Homicide during postictal psychosis. Epilepsy & Behavior Case Reports. https://doi.org/10.1016/j.ebcr.2014.04.001
160. Eison, M. S. (1989). The New Generation of Serotonergic Anxiolytics: Possible Clinical Roles. Psychopathology. https://doi.org/10.1159/000284622
161. Elhassan, N. M., Al‐Salihy, Z., Bushra, M., Sanabel, A.-A., Albobaly, Y., Eltorki, Y., & Alabdulla, M. (2018). Use of Benzodiazepines and Hypnotic Medications in Psychiatry Older Adult Outpatients. International Journal of Case Reports. https://doi.org/10.28933/ijcr-2018-11-1006
162. Emilien, G., Durlach, C., Minaker, K. L., Winblad, B., Gauthier, S., & Maloteaux, J. (2004). Behavioral and psychological impairments. Birkhäuser Basel eBooks. https://doi.org/10.1007/978-3-0348-7842-5_9
163. Erber, N. P., & Scherer, S. (1999). Sensory Loss and Communication Difficulties in the Elderly. Australasian Journal on Ageing. https://doi.org/10.1111/j.1741-6612.1999.tb00079.x
164. Escobedo, A. D. Á. (2012). Influencia del estrés y depresión prenatal en el desarrollo del niño. Revista Peruana de Pediatría. https://doi.org/10.61651/rped.2012v65n3p158-169
165. Esquiliano, G. R., Ramírez, I. M., Valdés, A. T., & Aguilar, C. A. T. (2004). Daño neurológico secundario a hipoxia isquemia perinatal. Archivos de neurociencias (México, D.F.).
166. Esteves-Sousa, D., Albuquerque, M., Facucho-Oliveira, J., Santos, P. E. D., Costa, M. S., Chai, M. V., Mendonça, L., & Tropa, J. (2019). ANTIPSYCHOTIC AGENTS, UNDERNEATH THEIR ACTION – STRENGTHS AND SHORTCOMINGS. https://doi.org/10.26226/morressier.5d1a037657558b317a14069b
167. Evers, M. M., & Marin, D. B. (2002). Mood disorders. Effective management of major depressive disorder in the geriatric patient.. PubMed.
168. Falk, A., Joseph, R., Smith, S., & Wilk, A. (2023). Mood and Anxiety Disorders: Major Depressive Disorder.. PubMed.
169. Farıdhosseını, F., & Zamani, A. (2012). A case report of somnambulism associated with olanzapine.. PubMed.
170. Fava, G. A., & Cosci, F. (2019). Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.19com12794
171. Feighner, J. P., & Boyer, W. F. (1989). Serotonin-IA Anxiolytics: An Overview. Psychopathology. https://doi.org/10.1159/000284623
172. Fellinger, M., Friedrich, F., Tabrizi, F. V., Baumgärtner, J., & Mossaheb, N. (2017). Hashimoto-Enzephalopathie. psychopraxis neuropraxis. https://doi.org/10.1007/s00739-017-0381-y
173. Fernández‐Jaén, A., Fernández‐Mayoralas, D. M., Pérez, B. C., Acero, N. M., & Jareño, N. M. (2008). Efectos del metilfenidato en los procesos cognitivo-atencionales. Uso de los test de ejecución continuada. Revista de Neurología. https://doi.org/10.33588/rn.46s01.2008002
174. Fernández‐Torre, J. L. (2010). Estado epiléptico no convulsivo en adultos en coma. Revista de Neurología. https://doi.org/10.33588/rn.5005.2009333
175. Filho, A. C. O., Gomes, L. M. T., Corrêa, A. C., Leão, E. F. D., Cangussu, D. M., & Torres, S. D. A. S. (2019). BRUXISMO DO SONO. Revista Intercâmbio.
176. Fine, L., Dubrovsky, B., & Spielman, A. J. (2011). Insomnia. BENTHAM SCIENCE PUBLISHERS eBooks. https://doi.org/10.2174/978160805153311101010137
177. Fingerhood, M. (2020). Sedatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0005
178. Fink, J. K., Filling‐Katz, M. R., Barton, N. W., Macrae, P. R., Hallett, M., & Cohen, W. E. (1988). Treatable Dystonia Presenting as Spastic Cerebral Palsy. PEDIATRICS. https://doi.org/10.1542/peds.82.1.137
179. Fink, J. K., Filling‐Katz, M. R., Barton, N. W., Macrae, P. R., Hallett, M., & Cohen, W. E. (1988). Treatable dystonia presenting as spastic cerebral palsy.. PubMed.
180. Fischer, T., Agar, M., Hosie, A., & Teodorczuk, A. (2020). Unpacking agitation in practice: a call for greater precision. Age and Ageing. https://doi.org/10.1093/ageing/afaa110
181. Fonseca, L. C., Tedrus, G. M. A. S., Lalloni, D. T., Tella, L. M. G., Maluf, P., & Sousa, V. D. D. (2005). Distúrbio cognitivo transitório associado a atividade epileptiforme generalizada ou difusa durante o eletrencefalograma. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/s0004-282x2005000500018
182. Forrest, J., Willis, L., Holm, K., Kwon, M. S., Anderson, M. A., & Foreman, M. D. (2007). Recognizing quiet delirium.. PubMed. https://doi.org/10.1097/01.naj.0000265267.77070.0c
183. Freitas, C., Mendes, A. M., & Queirós, S. (2016). The role of modified states of consciousness in drug use. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1012
184. Friedel, B. (1991). ARZNEIMITTEL UND STRASSENVERKEHR. Arzt und Auto.
185. Fronczek, R., Zande, W. L. M. V. D., Dijk, J. G. V., Overeem, S., & Lammers, G. J. (2007). [Narcolepsy: a new perspective on diagnosis and treatment].. PubMed.
186. Gabbard, G. O., & Atkinson, S. (1996). Study guide to treatments of psychiatric disorders. American Psychiatric Press eBooks.
187. Gagliardi, B., Luscher, V., Monin, Y., Kherad, O., & Coronado, L. (2021). [Sleep disturbances related to nocturnal nuisances in elderly inpatients].. PubMed.
188. Gallego, D., Figueroa, J., & Orozco, C. (2010). Síndrome de disfunción cognitiva de perros geriátrico. Revista Mvz Córdoba. https://doi.org/10.21897/rmvz.313
189. Gani, H. (2016). Risk Factors: Pathogenesis, Diagnosis and Management of Delirium. International Journal of Science and Research (IJSR). https://doi.org/10.21275/v5i4.nov162972
190. García, M. D. S., & Calderón, R. M. (2010). Síntomas no motores en la enfermedad de Parkinson y estimulación cerebral profunda. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009745
191. Garg, T., & Rawat, V. S. (2023). Trihexyphenidyl Use Disorder and Withdrawal Syndrome. Journal of Psychiatry Spectrum. https://doi.org/10.4103/jopsys.jopsys_12_23
192. Garro, A., Bond, G. R., & Gilbert, D. L. (2007). Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Clinical Toxicology. https://doi.org/10.1080/15563650600981178
193. Garza-Treviño, E. S. (1988). El manejo de urgencia de los cuadros psicóticos agudos. Salud Mental.
194. Gaudiano, B. A. (2012). The Need to Develop Innovative Interventions to Improve Treatment Adherence in Co-Occurring Severe Mental Illness and Substance Use Disorders. Journal of Addiction Research & Therapy. https://doi.org/10.4172/2155-6105.s8-e001
195. George, O., & Koob, G. F. (2017). Individual differences in the neuropsychopathology of addiction. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2017.19.3/gkoob
196. Ghosh, S. (2015). Better understanding of etiopathology needed to develop novel treatments. Medicus.
197. Ghosh, S., Singha, P. S., & Ghosh, D. (2023). Neuroprotective compounds from three common medicinal plants of West Bengal, India: a mini review. Exploration of neuroscience. https://doi.org/10.37349/en.2023.00030
198. Gi, S. (2011). [Neurophysiological and neurotransmitter mechanisms of behavior inhibition in normal and pathological conditions]..
199. Giannakopoulos, P., Hock, C., Wettstein, A., Schüpbach, B., & Müller‐Spahn, F. (2000). [Diagnosis and therapy of behavior disorders in dementia].. PubMed.
200. Golden, C. J., & Golden, Z. L. (2004). Traumatic Brain Injury. Routledge eBooks. https://doi.org/10.4324/9780203336960-19
201. Goldenberg, F. (2003). Other medications used for insomnia. SLEEP. https://doi.org/10.1007/978-1-4615-0217-3_22
202. Goldfeder, S., Scott, R., & Briggs, J. P. (2023). Forensic Assessments of Alcohol, Cannabis and Methamphetamine Intoxication in Cases of Violent Offending.. PubMed.
203. Goldstein, A. (2001). The Seesaw Brain: "Highs" and Adaptations. Addiction. https://doi.org/10.1093/oso/9780195146639.003.0006
204. Gordon, M. F., & Leder, A. (2012). Serotonin Syndrome. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-835-5_18
205. Goyal, A., Pallavi, K., & Awasthy, A. K. (2023). Reemergence of Neurological Deficit with Hyponatremia—When Obvious Is Not True. Journal of Neuroanaesthesiology and Critical Care. https://doi.org/10.1055/s-0042-1758459
206. Gracias, G., Garrison, S., & Allan, G. M. (2014). Statins and cognitive impairment.. PubMed.
207. Grajales, D. V. (2019). La posesión demoníaca: psicosis, neurosis histérica o trastorno neuropsicológico. Poiésis. https://doi.org/10.21501/16920945.3198
208. Graziani, P. (2011). La consommation excessive d’alcool chez la personne âgée. Drogues santé et société. https://doi.org/10.7202/1005300ar
209. Groppa, S., González‐Escamilla, G., Tinkhauser, G., Baqapuri, H. I., Sajonz, B., Wiest, C., Pereira, J. B., Herz, D. M., Dold, M., Bange, M., Ciolac, D., Almeida, V., Neuber, J., Mîrzac, D., Martín‐Rodríguez, J. F., Dresel, C., Muthuraman, M., Gomez, A. D. A., Navas, M., ... Coenen, V. A. (2023). Perspectives of Implementation of Closed-Loop Deep Brain Stimulation: From Neurological to Psychiatric Disorders. Stereotactic and Functional Neurosurgery. https://doi.org/10.1159/000535114
210. Groth, M., Much, C., & Fiehler, J. (2013). Manifestation of Acute Leriche Syndrome as Cauda Equina Syndrome. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. https://doi.org/10.1055/s-0032-1330431
211. Guamanarca, R. I. S., Loraque, N. B., Rubio, A. L., García, M. M., Lupiañez, I. J., & Llaría, M. M. M. (2025). SÍNDROME DE EKBOM EN PACIENTE GERIÁTRICO. A PROPÓSITO DE UN CASO.. Revista sanitaria de investigación.. https://doi.org/10.34896/rsi.2025.31.47.002
212. Guerdjikova, A. I., McElroy, S. L., Barger, S. D., Barth, J., Farrelly, S., & Brohan, E. (2019). Recent Advances in Depressive Disorder.
213. Gull, D. G., & Langford, N. (2006). Drugs and driving. Adverse Drug Reaction Bulletin. https://doi.org/10.1097/00012995-200606000-00001
214. Gupta, S., Laddha, A., Chaturvedi, P., Chaturvedi, N., Mishra, A., & Raghvendra, R. (2011). Trends and strategy towards therapies for status epilepticus: A decisive review. International Journal of Pharmaceutical Sciences Review and Research.
215. Guskiewicz, K. M., & Goldman, S. B. (2013). A Changing Landscape: Traumatic Brain Injury in Military Combat and Civilian Athletics. The FASEB Journal. https://doi.org/10.1096/fj.13-1101ufm
216. Gélinas, C., Klein, K., Naidech, A., & Skrobik, Y. (2013). Pain, Sedation, and Delirium Management in the Neurocritically Ill: Lessons Learned from Recent Research. Seminars in Respiratory and Critical Care Medicine. https://doi.org/10.1055/s-0033-1342986
217. Gërguri, A., Maloku, A., Zeka, N., Vuçitërna, A., Bejiqi, R., & Retkoceri, R. (2015). EEG as Prognostic Argument in First Afebril Seizures. Anglisticum Journal. https://doi.org/10.0001/(aj).v4i8.1205
218. Güleç, H., Babayiğit, M., Kurtay, A., Şahap, M., Ulus, F., Tutal, Z. B., & Horasanlı, E. (2014). Seizure due to multiple drugs intoxication: a case report. Brazilian Journal of Anesthesiology (English Edition). https://doi.org/10.1016/j.bjane.2014.02.013
219. Hainline, B., Gurin, L., & Torres, D. M. (2019). Cognitive Dysfunction Following Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0034
220. Hainline, B., Gurin, L., & Torres, D. M. (2019). Unmasking Neuropsychiatric Disorders Following Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0035
221. Hajak, G., Müller-Popkes, K., Riemann, D., Mayer, G., & Lauer, C. (1997). Psychologische, psychotherapeutische und andere nichtpharmakologische Therapieformen zur Behandlung der Insomnie. Fortschritte der Neurologie · Psychiatrie. https://doi.org/10.1055/s-2007-996317
222. Hall, S., & Ibrahim, S. (2023). 0998 Duloxetine as a Possible Effective Treatment of Klein-Levin Syndrome Case Report. SLEEP. https://doi.org/10.1093/sleep/zsad077.0998
223. Hamdani, H., Mtalai, N., Ennaki, S., Daghouj, G., Maaloum, L. E., Allali, B., & Kettani, A. E. (2023). Congenital Insensitivity TO Pain: A Case Report. European Journal of Medical and Health Sciences. https://doi.org/10.24018/ejmed.2023.5.4.1782
224. Hamed, S. A. (2014). Diabetes mellitus and the brain : special emphasis on cognitive function : review. The South African journal of diabetes & vascular disease.
225. Hamed, S. A. (2017). The auditory and vestibular toxicities induced by antiepileptic drugs. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2017.1372420
226. Hansen, N., Lipp, M., Vogelgsang, J., Vukovich, R., Zindler, T., Luedecke, D., Gingele, S., Malchow, B., Frieling, H., Kühn, S., Denk, J., Gallinat, J., Skripuletz, T., Moschny, N., Fiehler, J., Riedel, C., Wiedemann, K., Wattjes, M. P., Zerr, I., ... Neyazi, A. (2020). Autoantibody-associated psychiatric symptoms and syndromes in adults: A narrative review and proposed diagnostic approach. Brain Behavior & Immunity - Health. https://doi.org/10.1016/j.bbih.2020.100154
227. Hao, Y., Controzzi, M., Cipriani, C., Popović, D. B., Yang, X., Chen, W., Zheng, X., & Carrozza, M. C. (2013). Controlling hand-assistive devices: utilizing electrooculography as a substitute for vision. IEEE Robotics & Automation Magazine. https://doi.org/10.1109/mra.2012.2229949
228. Harding, S. (2005). Continuing Professional Development Managing delirium in older people.
229. Haywood, P., Divekar, N., & Karalliedde, L. (1999). Concurrent medication and the neuromuscular junction. European Journal of Anaesthesiology. https://doi.org/10.1097/00003643-199902000-00002
230. Heekerens, J. B., Gross, J. J., Kreibig, S. D., Wingenfeld, K., & Röpke, S. (2023). The Temporal Dynamics of Dissociation: Protocol for an Ecological Momentary Assessment and Laboratory Study in a Transdiagnostic Sample. https://doi.org/10.31234/osf.io/aq63g
231. Heim, E. (1989). [Psychogenic impaired consciousness].. PubMed.
232. Helbig, M., Youssef, N., & Schuetz, S. (2023). 1001 A Case of Unusual Nocturnal Movements Consistent with Paroxysmal Hypnogenic Dyskinesia. SLEEP. https://doi.org/10.1093/sleep/zsad077.1001
233. Hertz, L., Song, D., Li, B., Du, T., Xu, J., Gu, L., Chen, Y., & Liang, P. (2014). Signal Transduction in Astrocytes during Chronic or Acute Treatment with Drugs (SSRIs, Antibipolar Drugs, GABA-ergic Drugs, and Benzodiazepines) Ameliorating Mood Disorders. Journal of Signal Transduction. https://doi.org/10.1155/2014/593934
234. Heylens, G., Roosens, E., Mulier, J. P., & Fruyt, J. D. (2017). [The use of dexmedetomidine in extreme agitation].. PubMed.
235. Hollon, S. D., Stewart, M. O., & Strunk, D. R. (2005). Enduring Effects for Cognitive Behavior Therapy in the Treatment of Depression and Anxiety. Annual Review of Psychology. https://doi.org/10.1146/annurev.psych.57.102904.190044
236. Hong, C. (2013). 분과 심포지움 2. 임상 : 새로운 진단체계 DSM-5; 조현병 스펙트럼 및 기타 정신병적 장애,성격장애. 한국심리학회 연차 학술발표논문집.
237. Hong, C. (2013). 조현병 스펙트럼 및 기타 정신병적 장애, 성격장애. 한국심리학회 학술대회 자료집.
238. Horton, J. M. (1980). Use of anaesthesia. Care of the unconscious.. BMJ. https://doi.org/10.1136/bmj.281.6232.38
239. Housley, S. B., Patel, D., Nyabuto, E., & Reynolds, R. M. (2021). Spinal cord detethering without laminectomy or laminotomy. Surgical Neurology International. https://doi.org/10.25259/sni_942_2021
240. Huprich, S. K. (2010). Schizoid Personality Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0819
241. Inmaculada, M., & Pérez, P. B. (2016). Neuronal and behavioural effects of social isolation in old age.
242. Ishizuka, K., Shikino, K., Li, Y., Yokokawa, D., Tsukamoto, T., Yanagita, Y., Kojima, J., Yamashita, S., Noda, K., Uehara, T., & Ikusaka, M. (2023). The differential diagnosis of medical and psychogenic disease in primary care. Journal of General and Family Medicine. https://doi.org/10.1002/jgf2.661
243. İbiloğlu, A. O., Atlı, A., Kaya, M. C., Baran, A. S., & Sır, A. (2016). Psychogenic Gait Disorder After a Stressful Life Event: Case Report. Turkiye Klinikleri Journal of Case Reports. https://doi.org/10.5336/caserep.2015-46732
244. Jaffee, M. S., Broshek, D. K., & Svingos, A. M. (2023). What Is a Concussion?. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780190630119.003.0001
245. Jain, S. (2010). Computational and Evidence-based Medicine in Neuromodulation. Frontiers in Neuroengineering. https://doi.org/10.3389/conf.fneng.2010.10.00012
246. Jain, S., Goel, S., & Kapila, S. (2015). Clinical Evaluation Of Psychiatric Emergencies.
247. Jalal, B. (2018). The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology. https://doi.org/10.1007/s00213-018-5042-1
248. Judd, L. L., Schettler, P. J., Brown, E. S., Wolkowitz, O. M., Sternberg, E. M., Bender, B. G., Bulloch, K., Cidlowski, J. A., Kloet, E. R. D., Fardet, L., Joëls, M., Leung, D. Y., McEwen, B. S., Roozendaal, B., Rossum, E. F. C. V., Ahn, J., Brown, D. W., Plitt, A., & Singh, G. (2014). Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2014.13091264
249. Kaibuchi, K., & Tsuboi, D. (2010). Current perspective on the pathogenesis of schizophrenia from the viewpoint of risk factors such as DISC1 (corrected).
250. Kaiser, N., Hoza, B., & Hurt, E. (2008). Multimodal treatment for childhood attention-deficit/hyperactivity disorder. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.8.10.1573
251. Kales, A. (1990). Benzodiazepine Hypnotics and Insomnia. Hospital Practice. https://doi.org/10.1080/21548331.1990.11704103
252. Kallweit, M. S., Kallweit, N. P., & Kallweit, U. (2023). Pharmacological Treatments of Sleep-Wake Disorders: Update 2023. https://doi.org/10.20944/preprints202310.1257.v1
253. Kallweit, M. S., Kallweit, N. P., & Kallweit, U. (2023). Pharmacological Treatments of Sleep–Wake Disorders: Update 2023. Clinical and Translational Neuroscience. https://doi.org/10.3390/ctn7040042
254. Kanchanatawan, B., & Kasantikul, D. (2007). Antipsychotic-induced tardive movement disorders: a series of twelve cases.. PubMed.
255. Kane, J. M., & Mayerhoff, D. (1989). Do Negative Symptoms Respond to Pharmacological Treatment?. The British Journal of Psychiatry. https://doi.org/10.1192/s0007125000291630
256. Kanner, A. M., & LaFrance, W. C. (2015). Epilepsy and Seizures. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199731855.003.0043
257. Kap, Y. S. (2010). A Primate View on Multiple Sclerosis.
258. Kaplan, H., Sadock, B. J., & Cancro, R. (1991). Comprehensive Textbook of Psychiatry/V.. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-114-9-823_8
259. Kaprinis, G., Fountoulakis, K. Ν., & Kaprinis, S. (2002). Arguments against the Cognitive Dysmetria Hypothesis of Schizophrenia. Perceptual and Motor Skills. https://doi.org/10.2466/pms.2002.94.3.975
260. Kazymova, N., Kharlamenkova, N. Y., & Nikitina, D. A. (2019). Severe life events and their psychological consequences: loss or threat of loss of nearest. Vestnik Kostroma State University Series Pedagogy Psychology Sociokinetics. https://doi.org/10.34216/2073-1426-2019-25-2-96-101
261. Kelly, F. D. (2010). Adjustment Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0015
262. Kerchner, G. A., & Rosenbloom, M. (2014). Frontotemporal Neurocognitive Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg65
263. Kessels, R. P. C., & Savage, G. (2015). Amnestic Disorders. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp060
264. Killick, L., Carlyle, W., & Ancill, R. (1991). ECT: An Effective Treatment in the Screaming Demented Patient. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.1991.tb03610.x
265. Kim, H. A., Bisdorff, A., Bronstein, A. M., Lempert, T., Rossi-Izquierdo, M., Staab, J. P., Strupp, M., & Kim, J. (2019). Hemodynamic orthostatic dizziness/vertigo: Diagnostic criteria. Journal of Vestibular Research. https://doi.org/10.3233/ves-190655
266. Kim, J.-B., & Sung-Won, J. (2013). 공존하는 불안장애와 물질사용장애가 주요우울증에 미치는 영향.
267. Kintz, P., Villain, M., & Cirimele, V. (2008). Chemical Abuse in the Elderly: Evidence From Hair Analysis. Therapeutic Drug Monitoring. https://doi.org/10.1097/ftd.0b013e31816bac44
268. Kintz, P., Villain, M., Cirimele, V., Goullé, J., & Ludes, B. (2002). [Crime under the influence of psychoactive drugs: the problem of the duration of detection].. PubMed.
269. Klein, S. (2015). Autistic phenomena in neurotic patients 1. Routledge eBooks. https://doi.org/10.4324/9781315743882-10
270. Knaap, M. S. V. D., Depienne, C., Sedel, F., & Abbink, T. E. M. (2015). CLCN2-Related Leukoencephalopathy.
271. Knapp, P., & Lightbody, C. E. (2019). Emotional and Cognitive Changes Following a Stroke. https://doi.org/10.1002/9781119581161.ch11
272. Knupp, K. G., & Wirrell, E. (2014). Progressive myoclonic epilepsies. Neurology. https://doi.org/10.1212/wnl.0000000000000091
273. Ko, J. Y., Wolicki, S. B., Barfield, W. D., Patrick, S. W., Broussard, C. S., Yonkers, K. A., Naimon, R., & Iskander, J. (2017). CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome. MMWR Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm6609a2
274. Kokaçya, M. H., Çöpoğlu, Ü. S., Şahpolat, M., & Arı, M. (2015). A Case of Cannabis Use-Associated Psychotic Disorder Accompanied by Autoscopic Phenomena. Addicta The Turkish Journal on Addictions. https://doi.org/10.15805/addicta.2015.2.1.061e
275. Kokaçya, M. H., Çöpoğlu, Ü. S., Şahpolat, M., & Arı, M. (2016). Use of Modafinil in Psychiatric Disorders. Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry.
276. Konez, O., Pascual-Castroviejo, I., Rocco, C. D., & Ruggieri, M. (2008). Sturge-Weber Syndrome. https://doi.org/10.1007/978-3-211-69500-5_10
277. Koo, J.-S., Seo, B.-I., Park, J.-H., & Roh, S. (2010). Analysis of papers on Oriental herbal medicines(prescriptions and herbs) for dementia. The Korea Journal of Herbology. https://doi.org/10.6116/kjh.2010.25.3.131
278. Korn‐Lubetzki, I., Steiner‐Birmanns, B., Galperin, I., Benasouli, Y., & Steiner, I. (2007). NONCONVULSIVE STATUS EPILEPTICUS IN OLDER PEOPLE: A DIAGNOSTIC CHALLENGE AND A TREATABLE CONDITION. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2007.01284.x
279. Koshy, R., & Sudha, P. (2011). Nonconvulsive status epilepticus: An unusual cause of postoperative unresponsiveness following general anaesthesia. Indian Journal of Anaesthesia. https://doi.org/10.4103/0019-5049.79901
280. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
281. Krejcie, T. C., & Avram, M. J. (2011). When Duzitol Does Not Do It All. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0b013e3182251509
282. Kumagai, R., & Iseki, E. (2012). [Psychotropic medication of elderly patients].. PubMed.
283. Kumar, P. S., Krishnan, A., & Suresh, R. (2019). Escitalopram-induced extrapyramidal symptoms. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_331_18
284. Kusumadewi, A. F. (2020). Case Report: Magic Mushroom (Psilocybe Cubensis) Intoxication. Archives of The Medicine and Case Reports. https://doi.org/10.37275/amcr.v1i2.13
285. Lam, R. W. (2018). Associated clinical features. Depression. https://doi.org/10.1093/med/9780198804147.003.0005
286. Lam, R. W. (2018). Clinical features and diagnosis. Depression. https://doi.org/10.1093/med/9780198804147.003.0004
287. Lambert, M., Schimmelmann, B. G., Karow, A., & Naber, D. (2003). Subjective Well-being and Initial Dysphoric Reaction under Antipsychotic Drugs - Concepts, Measurement and Clinical Relevance. Pharmacopsychiatry. https://doi.org/10.1055/s-2003-45128
288. Landolt, H., & Borbély, A. A. (2000). Alkohol und Schlafstörungen.. Therapeutische Umschau.
289. Lanzaro, M. (2017). A new syndrome? The sport identification addiction and the case of Italian football ultra-fanatical support. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.508
290. Lawrie, S. M. (2010). Schizophrenia, bipolar disorder, obsessive–compulsive disorder, and personality disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.260507
291. Lejoyeux, M., & Adès, J. (1993). [Psychiatric emergencies in acute alcoholic intoxication].. PubMed.
292. Lemogne, C., Pitron, Jy, R., Limosin, F., & Cathébras, P. (2019). What attitude towards a patient with somatoform disorder?. PubMed.
293. Liberalesso, P. B. N. (2018). Epileptic Syndromes in Childhood. A Practical Approach. Residência Pediátrica. https://doi.org/10.25060/residpediatr-2018.v8s1-10
294. Loitman, J. E., & Deshields, T. L. (2010). Psychiatric Palliative Care Issues. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-590-3_4
295. Luthra, M. (2017). Depression: Current Scenario with reference to India. Indian Journal of Community Health. https://doi.org/10.47203/ijch.2017.v29i01.001
296. Macauley, R. (2018). Palliative Sedation (DRAFT). Oxford University Press eBooks. https://doi.org/10.1093/med/9780199313945.003.0009
297. Macias, C., Montaño, M. G., & Vega, D. (2015). Differential Diagnosis Between Neuroleptic Malignant Syndrome and Catatonia. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)30515-0
298. Maddocks, I., Brew, B. J., Waddy, H., & Williams, I. (2005). Cognitive, behavioural and psychological symptoms. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511545016.015
299. Magnin, É., Bustos, E. M. D., & Moulin, T. (2017). Pali and Echo Phenomena: Symptoms of Persistence and Perseveration. Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences. https://doi.org/10.1159/000475692
300. Majeske, M., Nistor, V., & Kellner, C. H. (2016). Late‐Life Psychosis. https://doi.org/10.1002/9781118654231.ch35
301. Maneeton, N., & Maneeto, B. (2013). Management of Delirium. InTech eBooks. https://doi.org/10.5772/52756
302. Marcello, S., & Silverstein, S. M. (2010). Schizophrenia. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0820
303. Marchesi, C., Tonna, M., & Maggini, C. (2008). Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse. The World Journal of Biological Psychiatry. https://doi.org/10.1080/15622970701459828
304. Marcos, D. I. P. (2007). Induced brain activity as indicator of cognitive processes : experimental-methodical analyses and algorithms for online-applications.
305. Maremmani, I., Pacini, M., Lamanna, F., Pani, P., Perugi, G., Deltito, J., Salloum, I. M., & Akiskal, H. S. (2010). Mood Stabilizers in the Treatment of Substance Use Disorders. CNS Spectrums. https://doi.org/10.1017/s1092852900027346
306. Martins, J. R. D. S., Vaz, R., Costa, A., Brás, J., Sousa, R., Abreu, J., Almeida, E., Andrade, R., Castro, N., & Casanova, T. (2023). Postpartum Delirium: A Psychosis Born in the 18th Century. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.2398
307. Martínez, A. R., Argüelles, P. P., Cucurella, M. M., Llort, A. J., Camacho, J. A., & Plana, J. C. (2008). Manifestaciones neurológicas en el síndrome hemolítico urémico. Revista de Neurología. https://doi.org/10.33588/rn.4704.2008249
308. Marvanová, M. (2016). Drug-induced cognitive impairment: Effect of cardiovascular agents. Mental Health Clinician. https://doi.org/10.9740/mhc.2016.07.201
309. Marzal, G. P., Rigual, F. C., Soto, B. B., & Olivares, J. Q. (2015). Psicoestimulantes en la infancia: ¿Medicalización o mejoramiento?.
310. Marzbani, H., Marateb, H. R., & Mansourian, M. (2016). Methodological Note: Neurofeedback: A Comprehensive Review on System Design, Methodology and Clinical Applications. Basic and Clinical Neuroscience Journal. https://doi.org/10.15412/j.bcn.03070208
311. Masiran, R., & Pang, N. T. P. (2017). Cognitive impairment and depressive symptoms coexisting in an elderly man. BMJ Case Reports. https://doi.org/10.1136/bcr-2016-218267
312. Mauri, M. C. (2016). Drug Induced Psychosis or Schizophrenia?. Dual Diagnosis Open Access. https://doi.org/10.21767/2472-5048.100011
313. Medina, S., & Fernando, D. (2019). Caso Christopher : El deseo, de deseo imposible en la neurosis obsesiva..
314. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
315. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
316. Meehl, P. E. (1989). Schizotaxia Revisited. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1989.01810100077015
317. Mehta, U. M., Kumar, C. N., Venkatasubramanian, G., & Thirthalli, J. (2013). Multimodal Sensory Distortions in Postpartum Exacerbation of Schizophrenia. Clinical Schizophrenia & Related Psychoses. https://doi.org/10.3371/csrp.meku.112013
318. Meier, L., Weinrebe, W., Annoni, J., & Petersen, J. A. (2022). Confusion and Hallucination in a Geriatric Patient. Pitfalls of a Rare Differential: Case Report of an Anti-LGI1-Encephalitis. Clinical Interventions in Aging. https://doi.org/10.2147/cia.s380316
319. Menzel, J. E., & Thompson, J. K. (2010). Food Addiction. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0365
320. Mercês, T. M. D. (2019). Controle hidroeletrolítico e respostas cardiovasculares à injeção central de angII, carbacol e hiperosmolaridade plasmática em ratos com epilepsia induzida por pilocarpina.
321. Meyer, J. S., & Hamel, A. F. (2014). Models of Stress in Nonhuman Primates and Their Relevance for Human Psychopathology and Endocrine Dysfunction. ILAR Journal. https://doi.org/10.1093/ilar/ilu023
322. Michel, J., Gisselbaek, A., Gauthey, L., & Zelger, G. L. (1993). [Non-compliant drug taking in elderly subjects].. PubMed.
323. Michie, S. (2002). CAUSES AND MANAGEMENT OF STRESS AT WORK. Occupational and Environmental Medicine. https://doi.org/10.1136/oem.59.1.67
324. Mihăicuţă, Ş., Muntean, D., Krohn, D., Marc, M., Fira‐Mladinescu, O., & Tudorache, V. (2006). [Excessive diurnal somnolence--causes, mechanisms, therapeutical approach].. PubMed.
325. Mikkelsen, M. E., & Iwashyna, T. J. (2020). Persistent problems and recovery after critical illness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0395
326. Mikkelsen, M. E., & Iwashyna, T. J. (2020). Persistent problems and recovery after critical illness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0395_update_001
327. Miller, S., Schwemmle, C., Jungheim, M., Kühn, D., & Ptok, M. (2015). [Medication-induced dysphagia : A review]..
328. Mills, D. S. (2014). Clinical animal behaviour models of stereotypic behaviour and underlying cognition.
329. Milovanović, S., Ćulafić, Đ. M., Leposavić, L., & Vojinovic, V. C. (2004). Hepatic encephalopathy in consultative psychiatry: Experience with chlomethiazole. Engrami.
330. Mimica, N., Presečki, P., Jukić, M. K., & Vitezić, D. (2017). Pharmacotherapy in Alzheimer's disease.
331. Misulis, K. E., & Murray, E. L. (2017). Mental Status Change. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190259419.003.0005
332. Miyata, H., Kono, J., & Yanagita, T. (2005). Clinical features of nicotine dependence.
333. Mizukami, K., Naito, Y., Yoshida, M., Nakanishi, T., & Koizumi, J. (1990). Mental Disorders Induced by Carbamazepine. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/j.1440-1819.1990.tb00441.x
334. MM, B., Islam, S., Nh, S., Rahman, M., & Bari, M. (2016). None. MOJ Orthopedics & Rheumatology. https://doi.org/10.15406/mojor.4.1
335. Montaño, M. G., Carmen, G. R., Ana, R., & Elena, G. (2016). Neuroleptic malignant syndrome. Differential diagnosis. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1608
336. Monteiro, R. B., Araújo, M., Samões, R., Norton, A., & Correia, A. P. (2021). Persistently positive <scp>anti‐NMDA</scp> receptor antibodies in chronic psychotic disorder: foe or innocent bystander?. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13275
337. Monti, M. M., Laureys, S., & Owen, A. M. (2010). The vegetative state. BMJ. https://doi.org/10.1136/bmj.c3765
338. Moore, D. P., & Puri, B. K. (2012). Textbook of Clinical Neuropsychiatry and Behavioral Neuroscience 3E.
339. Morell, I. B. (2011). Caracterització farmacològica de moduladors gabaèrgics per al tractament de l’insomni primari. TDX (Tesis Doctorals en Xarxa).
340. Moretti, R., Torre, P., Antonello, R. M., & Pizzolato, G. (2006). Atypical neuroleptics as a treatment of agitation and anxiety in Alzheimer’s disease: risks or benefits. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.6.5.705
341. Morin, C. M., & Edinger, J. D. (2008). Sleep/Wake Disorders. https://doi.org/10.1093/oso/9780195374216.003.0019
342. Morse, D. R., Martin, J. S., & Moshonov, J. (1991). Psychosomatically induced death: Relative to stress, hypnosis, mind control, and voodoo: Review and possible mechanisms. Stress Medicine. https://doi.org/10.1002/smi.2460070404
343. Mueller‐Pfeiffer, C., & Wittmann, L. (2013). Preliminary Investigation of the Reliability and Validity of the German Version of the State Scale of Dissociation (SSD). Journal of Traumatic Stress Disorders & Treatment. https://doi.org/10.4172/2324-8947.1000106
344. Mukim, M., Devi, S. L., Sharma, P., Joshef, M. R., Nagar, J. C., & Ahmad, N. (2019). ANESTHESIA AND ITS APPPLICATION. Indian Research Journal of Pharmacy and Science. https://doi.org/10.21276/irjps.2019.6.4.5
345. Mumdzhiev, H., & Slancheva, B. (2013). [Intrauterine hypotrophy and programming the health status. Late problems in newborns with intrauterine hypotrophy].. PubMed.
346. Méndez, A. V., Silva, P. L. N. D., Gonçalves, L. G. V., Chaves, S. C. D. S., Veiga, R. M., Mendez, A. E. R., Camilo, M. V. L., Mattos, L. C. D. A. N., Filho, M. R. S., Silva, R. D. G. D., Lima, G. F., Ferreira, C. S., & Santos, L. G. D. S. (2023). NEURONAL DAMAGE IN STATE EPILEPTICUS - LITERATURE REVIEW. International Journal of Health Science. https://doi.org/10.22533/at.ed.1593752318094
347. Müller, D., Angerer, V., Kithinji, J., Auwärter, V., Neurath, H., Liebetrau, G., Just, S., & Hermanns‐Clausen, M. (2016). Desoxypipradrol – eine neue (alte) Designerdroge. DMW - Deutsche Medizinische Wochenschrift. https://doi.org/10.1055/s-0042-107537
348. Na, I., & Volel, B. A. (2002). [Clinical aspects of "folie du doute"].. PubMed.
349. Nadeem, M. S., Murtaza, B. N., Al-Ghamdi, M. A., Ali, A., Zamzami, M. A., Khan, J. A., Ahmad, A., Rehman, M. U., & Kazmi, I. (2021). Autism - A Comprehensive Array of Prominent Signs and Symptoms. Current Pharmaceutical Design. https://doi.org/10.2174/1381612827666210120095829
350. Nahas-Vigon, J. H., & Fingerhood, M. (2025). Sedatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197796207.003.0005
351. Naidu, B. M. (2016). Drug Abuse in India. International journal of research in social sciences.
352. Nakamura, A., & Tanaka, K. (2023). A boy with dissociative symptoms who benefited from biopsychosocial assessment. Pediatrics International. https://doi.org/10.1111/ped.15502
353. Nakamura, M., & Inoue, Y. (2015). [Benzodiazepine and nonbenzodiazepine hypnotics].. PubMed.
354. Nelson, B., & Sass, L. A. (2018). 28.1 VARIETIES OF SELF DISORDER: A BIO-PHENO-SOCIAL MODEL OF SCHIZOPHRENIA. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sby014.116
355. Nelson, J. D., & Chouinard, G. (1999). Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology.. PubMed.
356. Neto, L. C. D. S., Miranda, G. A., Cunha, L. L. G. D., Canto, B. E. S., Strufaldi, V. P., Tetti, M. F., Akerman, M., & Matos, L. L. D. (2013). Consequências individuais e socioeconômicas da síndrome da apneia obstrutiva do sono. ABCS Health Sciences. https://doi.org/10.7322/abcshs.v38i1.6
357. Neubauer, D. N., Minkel, J., & Krystal, A. D. (2008). Pharmacologic Treatment of Insomnia. Psychiatry. https://doi.org/10.1002/9780470515167.ch105
358. Neufeld, K. J., Needham, D. M., Oh, E. S., Wilson, L. M., Nikooie, R., Zhang, A., Koneru, M., Balagani, A., Singu, S., Aldabain, L., & Robinson, K. A. (2019). Antipsychotics for the Prevention and Treatment of Delirium. https://doi.org/10.23970/ahrqepccer219
359. Nishino, S., Sakai, N., Mishima, K., Mignot, E., & Dement, W. C. (2017). Sedative-Hypnotics. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615371624.as43
360. Nivoli, G., Lorettu, L., Veneto, L. I., Milia, P., Nivoli, L., & Nivoli, A. (2006). Problemi gestionali delle gravi manifestazioni aggressive : Criminalità e spettro dell'umore. https://doi.org/10.1400/91497
361. Norman, E. M., Ferner, R. E., & Rawlins, M. D. (1995). Effects of drugs on behaviour. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198548263.003.0005
362. Ohta, T. (1996). [Recent progress in development of psychotropic drugs (5)--Hypnotics].. PubMed.
363. Olson, D. M., Westermarck, T., & Ekvall, S. W. (2005). Seizures And Epilepsy. https://doi.org/10.1093/oso/9780195165647.003.0010
364. Osterman, J. E., Erdos, B. Z., Oldham, M., & Ivkovic, A. (2010). Antidepressant Treatments in PTSD. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-435-7_7
365. Ozdemir, D., & Sahni, S. (2019). Conversion Disorder (Functional Neurological Symptom Disorder) Masquerading as Multiple Sclerosis: A Case Report. Cureus. https://doi.org/10.7759/cureus.4893
366. Pa, U., Régli, F., & Naegeli, C. (1989). [Various encephalopathies caused by drugs].. PubMed.
367. Page, C. E., & Coutellier, L. (2018). Reducing inhibition: A promising new strategy for the treatment of schizophrenia. EBioMedicine. https://doi.org/10.1016/j.ebiom.2018.07.043
368. Pagel, J., Pandi‐Perumal, S. R., & Monti, J. M. (2018). Treating insomnia with medications. Sleep Science and Practice. https://doi.org/10.1186/s41606-018-0025-z
369. Paradela, E. M. P. (2011). Depressão em idosos. Revista Hospital Universitário Pedro Ernesto (TÍTULO NÃO-CORRENTE). https://doi.org/10.12957/rhupe.2011.8850
370. Park, S., Kim, Y., & Lee, J. (2012). A Case of Blonanserin-Induced Mania in Schizophrenia. Korean Journal of Schizophrenia Research. https://doi.org/10.16946/kjsr.2012.15.1.46
371. Parker, R. S. (2012). Chronic Posttraumatic Disorders of Consciousness. CRC Press eBooks. https://doi.org/10.1201/b10562-14
372. Parker, R. S. (2012). Introduction to the Postconcussion Syndrome. CRC Press eBooks. https://doi.org/10.1201/b10562-2
373. Partinen, M., Huutoniemi, A., Kajaste, S., Lagerstedt, R., Markkula, J., Mäkinen, E., Paakkari, I., Partonen, T., Polo, P., Saarenpää‐Heikkilä, O., Seppälä, M., Kukkonen-Harjula, K., & Tuunainen, A. (2016). [Update on Current Care Guideline: Insomnia].. PubMed.
374. Parčina, M. (2017). ORGANIZACIJA RADA USTANOVE ZA ZAPOŠLJAVANJE, RAD I PROFESIONALNU REHABILITACIJU OSOBA S INVALIDITETOM.
375. Pascual‐Leone, Á., Ramachandran, V. S., Cole, J., Sala, S. D., Manly, T., Mayes, A. R., & Sacks, O. (2011). The Paradoxical Brain. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511978098
376. Patel, A., Moreland, T., Haq, F., Siddiqui, F., Mikul, M., Qadir, H., & Raza, S. (2011). Persistent Psychosis After a Single Ingestion of “Ecstasy” (MDMA). The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01200
377. Patricia, G. C. C., AAngela, G.-M., & Marina, R.-A. (2017). Diagnostic and therapeutical challenges of late-onset psychosis.. Journal of Psychology and Cognition. https://doi.org/10.35841/psychology-cognition.2.4.218-220
378. Paw, H., & Shulman, R. (2014). Management of status epilepticus. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781316182673.042
379. Pechnick, R. N., Cunningham, K. A., & Danovitch, I. (2014). Hallucinogen-Related Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg51
380. Peitl, M. V., Prološčić, J., Zelić, S. B., Skarpa-Usmiani, I., & Peitl, V. (2011). Symptoms of agitated depression and/or akathisia.. PubMed.
381. Petit, J., & Sansone, R. A. (2011). A Case of Interdose Discontinuation Symptoms With Venlafaxine Extended Release. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01140
382. Pfeffer, G., Chouinard, G., & Margolese, H. C. (2005). Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200505000-00011
383. Phu, T., Remmers, A., Schytz, H. W., Schankin, C. J., Nelson, S. E., Obermann, M., Hansen, J. M., Sinclair, A. J., Gantenbein, A. R., & Schoonman, G. (2018). Red and orange flags for secondary headaches in clinical practice. Neurology. https://doi.org/10.1212/wnl.0000000000006697
384. Pinzon, R. T., Meliala, L., & Sutarni, S. (2015). Epilepsi dan Gangguan Spektrum Autistik.
385. Pontius, A. A. (1993). NEUROPSYCHIATRIC UPDATE OF THE CRIME "PROFILE" AND "SIGNATURE" IN SINGLE OR SERIAL HOMICIDES: RULE OUT LIMBIC PSYCHOTIC TRIGGER REACTION. Psychological Reports. https://doi.org/10.2466/pr0.1993.73.3.875
386. Pontius, A. A. (1993). Neuropsychiatric Update of the Crime “Profile” and “Signature” in Single or Serial Homicides: Rule out Limbic Psychotic Trigger Reaction<sup>1</sup>. Psychological Reports. https://doi.org/10.1177/00332941930733pt125
387. Popescu, D., Popescu, G., Lupu, G., Panus, V., Neagu-Sadoveanu, S., & Buda, O. (2010). Drugs effects on the central nervous system. Forensic implications. Romanian Journal of Legal Medicine. https://doi.org/10.4323/rjlm.2010.231
388. Potvin, O., Hudon, C., Grenier, S., & Préville, M. (2010). Non-essential symptoms of depression and cognitive impairment no dementia (CIND) in community-dwelling elders without dysphoria or anhedonia. International Psychogeriatrics. https://doi.org/10.1017/s1041610210001419
389. Prasad, K., Prasad, M., Ramaratnam, S., & Marson, A. G. (2015). Status epilepticus. https://doi.org/10.1002/9781119067344.ch9
390. Pratibha, S. (2010). Etiology of Late Onset Seizures.
391. Pretl, M. (2019). Hypnotic drugs in treating insomnia. Klinická farmakologie a farmacie. https://doi.org/10.36290/far.2019.006
392. Pälvimäki, E.-P., Siironen, J., Pohjola, J., & Hernesniemi, J. (2011). [Brain concussion].. PubMed.
393. Płytycz, B., & Seljelid, R. (2002). Stress and immunity: minireview.. PubMed.
394. Qamar, A., Kotha, K., & Ioachimescu, O. C. (2011). Obstructive Sleep Apnea. BENTHAM SCIENCE PUBLISHERS eBooks. https://doi.org/10.2174/978160805267711101010021
395. Quartini, A., Pacitti, F., Bersani, G., & Iannitelli, A. (2018). From Adolescent Neurogenesis to Schizophrenia: Opportunities, Challenges and Promising Interventions. Biomedical Reviews. https://doi.org/10.14748/bmr.v28.4452
396. Quintero, J. M. B., Castellanos, A., & Santos, L. S. D. L. (2018). Efectividad de una intervención pre-quirúrgica de enfermería; en ansiedad de pacientes sometidos a colecistectomía del Hospital General Regional No.1 Vicente Guerrero de Acapulco, 2017.
397. Rades, M., & Wulandari, A. J. (2016). Skizoafektif Tipe Campuran. Jurnal Medula.
398. Raičević, B., Janković, S. V., Gojak, R., Dabanović, V., & Јаnkovic, S. (2023). Long-term outcomes in refractory status epilepticus. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2023.2292143
399. Ramey, T., & Regier, P. S. (2018). Cognitive impairment in substance use disorders. CNS Spectrums. https://doi.org/10.1017/s1092852918001426
400. Ranganathan, A., & Beitman, B. D. (1998). Panic disorder: a different perspective.. PubMed.
401. Rastogi, R., Swarm, R. A., Patel, T., & Riou, B. (2011). Case Scenario: Opioid Association with Serotonin Syndrome. Anesthesiology. https://doi.org/10.1097/aln.0b013e31823940c0
402. Realpe, B. L. C. (2013). Estudio comparativo de la acción psicofarmacológica y analgésica de extractos de plantas de uso terapéutico tradicional con antidepresivos inhibidores selectivos de la recaptación de monoaminas.
403. Ribeiro, J., Pestana‐Santos, A., & Madeira, N. (2017). Défices Cognitivos na Perturbação Depressiva Major. https://doi.org/10.25752/psi.12761
404. Ridder, D. D. (2007). Brain and Nerve Stimulation for Mood Enhancement. Philosophica. https://doi.org/10.21825/philosophica.82182
405. Riemann, D. (2014). Nicht pharmakologische Insomnietherapie. Therapeutische Umschau. https://doi.org/10.1024/0040-5930/a000611
406. Riofrío, I. P. B., Jefe, M., De, D., Mental, S., Miller, H., Mt, S., Psiquiatría, D., Dra, H., Velastegui, G. N. J., medico, Psc, R., Alexandra, C., & Torres, L. (2019). Síndrome Neuroléptico Maligno: A propósito de un caso clínico. https://doi.org/10.36015/cambios.v16.n1.2017.279
407. Ritz, L., Pitel, A., Vabret, F., Eustache, F., & Beaunieux, H. (2012). Alcoolodépendance : atteintes neuropsychologiques et diagnostics différentiels. Revue de neuropsychologie. https://doi.org/10.1684/nrp.2012.0227
408. Rivas-Vazquez, R. A., Carrazana, E., Rey, G., & Wheeler, S. D. (2000). SELECTIVE SEROTONIN REUPTAKE INHIBITOR DISCONTINUATION SYNDROME: THREE CASES PRESENTING TO A NEUROLOGIC PRACTICE. The Neurologist. https://doi.org/10.1097/00127893-200006060-00005
409. Robertson, O. D., Coronado, N. G., Sethi, R., Berk, M., & Dodd, S. (2019). Putative neuroprotective pharmacotherapies to target the staged progression of mental illness. Early Intervention in Psychiatry. https://doi.org/10.1111/eip.12775
410. Robinson, C. P., & Hocker, S. E. (2019). Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190862923.003.0098
411. Robison, D., & Hunt, S. D. (2005). Sudden In-Custody Death Syndrome.
412. Rohde, P., Lewinsohn, P. M., & Seeley, J. R. (1991). Comorbidity of unipolar depression: II. Comorbidity with other mental disorders in adolescents and adults.. Journal of Abnormal Psychology. https://doi.org/10.1037/0021-843x.100.2.214
413. Ronad, S. V., Patail, C. S., Gondbal, S. H., TC, K., Ronad, M., Pankaja, T., Badesgol, R., & Singhal, P. K. J. (2019). Professionals in metro cities suffer from anxiety disorder. Nursing & Care Open Access Journal. https://doi.org/10.15406/ncoaj.2019.06.00198
414. Roques, B. (2000). La dangerosité des drogues : mécanismes neurobiologiques des addictions et approches thérapeutiques.. médecine/sciences. https://doi.org/10.4267/10608/1588
415. Roth, T., Krystal, A. D., & Lieberman, J. A. (2007). Long-term issues in the treatment of sleep disorders.. CNS Spectrums.
416. Rucci, J. M., & Feinstein, R. E. (2014). Neurocognitive Disorders and Mental Disorders Due to Another Medical Condition. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199326075.003.0005
417. Ruggieri, V., & Arberas, C. (2013). [Non-epileptic motor paroxysmal phenomena in wakefulness in childhood].. PubMed.
418. Saccomano, S. J. (2012). Dizziness, vertigo, and presyncope. The Nurse Practitioner. https://doi.org/10.1097/01.npr.0000422206.92550.5b
419. Saeed, M. A. A. (2017). Management of tinnitus patient. International Journal of Growth and Development. https://doi.org/10.25081/ijgd.2017.v1i1.44
420. Saeed, S. A., & Tj, B. (1998). Panic disorder: effective treatment options.. PubMed.
421. Sahakian, B. J., & Morein‐Zamir, S. (2011). Depression and resilience: insights from cognitive, neuroimaging, and psychopharmacological studies. Oxford University Press eBooks. https://doi.org/10.1093/acprof:oso/9780199600434.003.0023
422. Saleh, S. C. (2023). Anesthesia-Related in Recovery Room Complication: Coma and Delayed Emergence. Jurnal Komplikasi Anestesi. https://doi.org/10.22146/jka.v1i1.5532
423. Sanchis‐Segura, C., & Spanagel, R. (2006). REVIEW: Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addiction Biology. https://doi.org/10.1111/j.1369-1600.2006.00012.x
424. Sandi, C. (2013). Stress and cognition. Wiley Interdisciplinary Reviews Cognitive Science. https://doi.org/10.1002/wcs.1222
425. Santarcangelo, E. L., Jambrick, Z., Sebastiani, L., Ghelarducci, B., & Picano, E. (2003). Hypnotic Susceptibility and Hypnosis Modulate the Endothelial Response to Acute Stress. Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale. https://doi.org/10.4081/jbr.2003.10561
426. Sanz, G. L., Ruíz, E. C., & Vázquez, L. S. (2015). Síndrome confusional ag udo en pacientes de edad avanzada con fractura de fémur. Ágora de enfermería.
427. Sardiani, S. (2023). Aplikasi Asuhan Keperawatan Jiwa Pada Tn. A Dengan Gangguan Persepsi Sensori:Halusinasi Pendengaran Diruangan Dolok Sanggul II. https://doi.org/10.31219/osf.io/kyqd2
428. Sarkar, S., Bhatia, G., & Dhawan, A. (2023). Clinical Practice Guidelines for Assessment and Management of Patients with Substance Intoxication Presenting to the Emergency Department. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_490_22
429. Sass, L. A. (2003). “Negative Symptoms,” Commonsense, and Cultural Disembedding in the Modern Age. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511616297.015
430. Sazonov, S. (2014). EPA-0651 – The complexity of psychopathological symptom as a possible indication of mental disease's etiology. European Psychiatry. https://doi.org/10.1016/s0924-9338(14)78023-x
431. Schildkrout, B. (2011). Specific Mental Signs and Symptoms. https://doi.org/10.1002/9781118083598.ch9
432. Schildkrout, B. (2014). Delirium. https://doi.org/10.1002/9781394260447.ch2
433. Schildkrout, B. (2014). Disease #57: <scp>REM</scp> Sleep Behavior Disorder. https://doi.org/10.1002/9781394260447.ch85
434. Schildkrout, B. (2014). Hallucinations. https://doi.org/10.1002/9781394260447.ch8
435. Schildkrout, B. (2014). Mood, Affect, and Emotion. https://doi.org/10.1002/9781394260447.ch4
436. Schutte, M., Mathias, B., & Hopf, G. (1988). [Adverse effects of antihistaminics].. PubMed.
437. Schweitzer, J. B. (2010). Attention‐Deficit/Hyperactivity Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0096
438. Schönknecht, P., Allgaier, A., Henkel, V., Hegerl, U., & Mergl, R. (2011). Psychopharmako- und Psychotherapie bei Patienten mit minorer Depression. Nervenheilkunde. https://doi.org/10.1055/s-0038-1628444
439. Seeman, P., & Seeman, M. V. (2011). Schizophrenia and the supersensitive synapse. Neuropsychiatry. https://doi.org/10.2217/npy.11.18
440. Sejdić, E., Malandraki, G. A., & Coyle, J. L. (2018). Computational Deglutition: Using Signal- and Image-Processing Methods to Understand Swallowing and Associated Disorders [Life Sciences]. IEEE Signal Processing Magazine. https://doi.org/10.1109/msp.2018.2875863
441. Seri, S., Cerquiglini, A., & Harding, G. F. A. (2006). Visually induced syncope: A nonepileptic manifestation of visual sensitivity?. Neurology. https://doi.org/10.1212/01.wnl.0000225058.42180.c2
442. Shaikh, A., Sirajuddin, S. M., Mukadam, M., & Ansari, S. A. (2017). Therapeutic Effect of “Nutool” in the Management of Sehar (Insomnia): A Review. https://doi.org/10.37591/rrjoush.v4i3.51
443. Shams, J., Rahmani, B., Asefi, F., & Daneshfar, S. (2010). CATATONIA DEVELOPMENT IN A SCHIZOAFFECTIVE PATIENT FOLLOWING ELECTROCONVULSIVE THERAPY: CASE REPORT.
444. Shankar, R., Wilcock, M., Oak, K., McGowan, P., & Sheehan, R. (2018). Stopping, rationalising or optimising antipsychotic drug treatment in people with intellectual disability and/or autism. Drug and Therapeutics Bulletin. https://doi.org/10.1136/dtb.2018.000009
445. Shaughnessy, A. F. (2020). Some Drugs Slightly Improve Cognition in People with Dementia; Effects on Behavioral or Psychological Symptoms Remain Unclear.. PubMed.
446. Sheets, E. S., & Brosse, A. L. (2010). Major Depressive Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0522
447. Shende, V., & Patel, F. R. (2014). AGMATINE AMELIORATES SOCIAL ISOLATION INDUCED OBSESSIVE-COMPULSIVE BEHAVIOR IN MICE.
448. Shibasaki, H., & Hallett, M. (2016). Psychogenic Neurologic Diseases. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190240974.003.0026
449. Shorvon, S. (2011). Super‐refractory status epilepticus: An approach to therapy in this difficult clinical situation. Epilepsia. https://doi.org/10.1111/j.1528-1167.2011.03238.x
450. Siddiqui, J. A., Qureshi, S. F., & Ghamdi, A. K. A. (2017). Alien Abductions: A Case of Sleep Paralysis. Sleep and Hypnosis. https://doi.org/10.5350/sleep.hypn.2017.19.0144
451. Silva, L. I. F. D., Souza, L. M., Gonzales, M. F., & Jurado, S. R. (2015). SLEEP DISORDERS IN CHILDHOOD. Simpósio Internacional de Neurociências da Grande Dourados.
452. Silver, R. M., & Airoldi, J. (2016). 27. Inherited thrombophilia. CRC Press eBooks. https://doi.org/10.1201/9781315200910-28
453. Simbolon, N. Y., Sitorus, T. R., Meliala, T. L., & Waruwu, P. (2020). TINJAUAN KRIMINOLOGI TERHADAP ANAK YANG MELAKUKAN TINDAK PIDANA PENYALAHGUNAAN NARKOTIKA. JURNAL ILMIAH SIMANTEK.
454. Simor, P., Demeter, G., Dobó, Z., Lázár, A. S., Csigó, K., Racsmány, M., & Harsányi, A. (2015). A kronotípus és az alvásminõség szerepe a mentálismegbetegedések tünettanában és prognózisában.
455. Singh, G., & Kaur, P. (2017). ANTIPSCYHOTIC INDIAN HERBAL FORMULATIONS: AN OVERVIEW. Indian Research Journal of Pharmacy and Science. https://doi.org/10.21276/irjps.2017.4.1.6
456. Singh, P., Anuradha, S., & Jahan, M. (2014). Efficacy of Cognitive Remediation in EpilepsyEfficacy of Cognitive Remediation in Epilepsy. JOURNAL OF PSYCHOSOCIAL RESEARCH.
457. Singh, S. (2015). Mental health in infancy. International Journal of Clinical & Medical Imaging. https://doi.org/10.4172/2376-0249.1000393
458. Smith, G. T., Zapolski, T. C. B., Combs, J. L., & Friend, R. E. (2010). Impulsivity. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0436
459. Smith, H. S. (2006). Hibernating Peripheral Nerve. Journal of Neuropathic Pain & Symptom Palliation. https://doi.org/10.3109/j426v02n02_02
460. Smith, H. S., & Jackson, K. C. (2008). Optimizing pharmacologic outcomes: Drug selection. https://doi.org/10.1093/oso/9780195339499.003.0005
461. Smitherman, T. A., & Rogers, D. G. (2020). Insomnia. The Wiley Encyclopedia of Health Psychology. https://doi.org/10.1002/9781119057840.ch181
462. Soares, E. B., Pires, J. B., Menezes, M. D. A., Santana, S. K. S. D., & Fraga, J. (2010). Fonoaudiologia X ronco/apneia do sono. Revista CEFAC. https://doi.org/10.1590/s1516-18462010000200019
463. Soffer‐Dudek, N. (2017). Arousal in Nocturnal Consciousness: How Dream- and Sleep-Experiences May Inform Us of Poor Sleep Quality, Stress, and Psychopathology. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2017.00733
464. Soler, C. L. (2008). Las reacciones postraumáticas en la infancia y adolescencia maltratada: el trauma complejo. Revista de Psicopatología y Psicología Clínica. https://doi.org/10.5944/rppc.vol.13.num.3.2008.4057
465. Solimini, R., Rotolo, M. C., Pichini, S., & Pacifici, R. (2017). Neurological Disorders in Medical Use of Cannabis: An Update. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527316666170413105421
466. Solmi, M., Bortolato, B., Veronese, N., Stubbs, B., Herrmann, N., & Carvalho, A. F. (2019). Pharmacological Interventions for Cognitive Dysfunction in Major Depressive Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198810940.003.0018
467. Sommer, I. E., & Arango, C. (2017). Moving interventions from after to before diagnosis. World Psychiatry. https://doi.org/10.1002/wps.20454
468. Sparmann, M., & Müller, D. (2017). Ungewöhnliche attackenweise Einschlafstörungen Unusual attack-like sleep onset disturbances. Nervenheilkunde. https://doi.org/10.1055/s-0038-1627037
469. Spiegel, E. P., & Vanderploeg, R. D. (2010). Postconcussion Syndrome. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0696
470. Sriramoju, M., Keerthi, V. P., Alumdri, D. B., & Akula, S. (2014). Evaluation of antidepressant activity of ethanolic and aqueous extract of Solanum tuberosum peel. Journal of Comprehensive Pharmacy. https://doi.org/10.37483/jcp.2014.1503
471. Stafstrom, C. E. (1995). Neonatal Seizures. Pediatrics in Review. https://doi.org/10.1542/pir.16.7.248
472. Stahl, S. M. (2006). Positive findings for negative symptoms of schizophrenia: no longer untreatable?. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.2006.00904.x
473. Stanley, R. O., & Burrows, G. D. (2001). The Negative Consequences of Hypnosis Inappropriately or Ineptly Applied. https://doi.org/10.1002/0470846402.ch23
474. Stasolla, F. (2020). Teaching Communication Skills in Children and Adolescents with Severe To Profound Neurodevelopmental Disorders through Aided-Alternative and Augmentative Strategies. International Journal of Psychology and Psychoanalysis. https://doi.org/10.23937/2572-4037.1510045
475. Steffens, D. C., Blazer, D. G., & Beyer, J. L. (2013). Mood Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781615370016.mt05
476. Stone, J., Pal, S., Blackburn, D., Reuber, M., Thekkumpurath, P., & Carson, A. (2015). Functional (Psychogenic) Cognitive Disorders: A Perspective from the Neurology Clinic. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-150430
477. Stubbe, D. (2007). Child and adolescent psychiatry : a practical guide. Lippincott Williams & Wilkins eBooks.
478. Stubbs, B. (2011). Displays of inappropriate sexual behaviour by patients with progressive cognitive impairment: the forgotten form of challenging behaviour?. Journal of Psychiatric and Mental Health Nursing. https://doi.org/10.1111/j.1365-2850.2011.01709.x
479. Summers, C. B. (2007). Cognitive-Behavior Group Therapy in Residential Treatment. https://doi.org/10.4324/9780203941157-16
480. Swann, A. C. (2012). Impulsivity and Affective Regulation. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780195389715.013.0084
481. Sweet, G., Kim, S., Martin, S. A., Washington, N. B., & Brahm, N. C. (2017). Psychiatric symptoms and synthetic cannabinoid use: Information for clinicians. Mental Health Clinician. https://doi.org/10.9740/mhc.2017.07.156
482. Szyguła‐Jurkiewicz, B., Szymik, M., Mrozowska, B., Schmidt, B., & Michalak, A. (2011). Psychologiczne uwarunkowania i konsekwencje ostrego zawału serca. Leki psychotropowe u chorych po ostrym zawale serca. Choroby Serca i Naczyń.
483. Söderpalm, B. (2002). Anticonvulsants: aspects of their mechanisms of action. European Journal of Pain. https://doi.org/10.1053/eujp.2001.0315
484. Tacn, A. (2012). PTSD in the Context of Malignant Disease. InTech eBooks. https://doi.org/10.5772/27424
485. Tait, G. (2006). A disordered approach. Office of Education Research; Faculty of Education.
486. Tan, B. L. W., & Gudi, A. (2021). A rare case: Mania associated with pazopanib. Proceedings of Singapore Healthcare. https://doi.org/10.1177/20101058211023778
487. Tang‐Wai, D. F., Josephs, K. A., & Petersen, R. C. (2005). Alzheimer's disease: overview. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544873.029
488. Tatsuzawa, Y., Ono, Y., Takahashi, T., Yoshino, A., & Nomura, S. (2011). Case of isolated adrenocorticotropic hormone deficiency mimicking major depressive disorder. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/j.1440-1819.2011.02207.x
489. Tempelhoff, R., Kofke, W. A., & Dasheiff, R. M. (1997). Anesthetic Implications of Epilepsy, Status Epilepticus, and Epilepsy Surgery. Journal of Neurosurgical Anesthesiology. https://doi.org/10.1097/00008506-199710000-00011
490. Thakur, A., Choudhary, D., Kumar, B., & Chaudhary, A. (2021). A Review on Post-traumatic Stress Disorder (PTSD): Symptoms, Therapies and Recent Case Studies. Current Molecular Pharmacology. https://doi.org/10.2174/1874467214666210525160944
491. Thomas, N., & Pantelis, C. (2015). Psychotic Disorders. The Encyclopedia of Clinical Psychology. https://doi.org/10.1002/9781118625392.wbecp535
492. Thomas, P., & Hazif‐Thomas, C. (2008). NEWLY UNDERSTANDING DEPRESSION IN ELDERLY. Gerontologie et societe.
493. Thomas, P., Hazif‐Thomas, C., & Clément, J. (2008). [Loss of motivation in the elderly].. HAL (Le Centre pour la Communication Scientifique Directe).
494. Tickner, N., Apps, J., Keady, S., & Sutcliffe, A. (2012). An overview of drug therapies used in the treatment of dystonia and spasticity in children. Archives of Disease in Childhood Education & Practice. https://doi.org/10.1136/archdischild-2011-301170
495. Tito, E., Knapp, B., Bucca, A., & Espiridion, E. D. (2019). A Case Report of Schizoaffective Disorder with Pseudoseizures in a 42-year-old Male. Cureus. https://doi.org/10.7759/cureus.4835
496. Todd, O., & Teale, E. (2017). Delirium: a guide for the general physician. Clinical Medicine. https://doi.org/10.7861/clinmedicine.17-1-48
497. Torpy, J. M. (2010). Delirium. JAMA. https://doi.org/10.1001/jama.304.7.814
498. Townsend, M. C. (2004). Nursing diagnoses in psychiatric nursing : care plans and psychotropic medications. F.A. Davis Co. eBooks.
499. Trojanowska, M. (2017). Społeczny i medyczny wymiar seksualności osób z niepełnosprawnością na przykładzie osób chorych na stwardnienie rozsiane. Acta Universitatis Lodziensis Folia Sociologica. https://doi.org/10.18778/0208-600x.60.08
500. Tseng, Y., Wellman, S. E., & Ho, I. (2020). Sedative-Hypnotics: Addiction and Current Research Status. Journal of Food and Drug Analysis. https://doi.org/10.38212/2224-6614.3068
501. Tso, I. F., Chun, J., & Deldin, P. J. (2010). Schizoaffective Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0818
502. Unknown (2010). Combination of Oral Clonidine and Midazolam as Premedication When Ketamine is not an Option in an Uncooperative Autistic Patient. The Internet Journal of Anesthesiology. https://doi.org/10.5580/270c
503. Unknown (2010). Effects of age on drug action. Nursing Older People. https://doi.org/10.7748/nop.22.5.13.s21
504. Urakov, T., & Hart, R. (2017). Intoxicants. Routledge eBooks. https://doi.org/10.4324/9781315382760-68
505. Urazán, D. T., Barragán, A. G., Hernández, K. D. C. P., & Gamboa, D. J. (2023). Afasia primaria progresiva variante no fluente/agramática. Acta neurológica colombiana. https://doi.org/10.22379/anc.v39i3.853
506. Uysal, C., & Albayrak, Y. (2013). IMIPRAMINE INDUCED ACUTE DYSTONIA IN A CHILD WITH ENURESIS NOCTURNA.
507. Vallée, J.-P. (2010). Énurésie nocturne : informer/conseiller, évaluer, traiter. Médecine.
508. Vanderschuren, L. J. M. J. (2008). Neurobehavioral Mechanisms of Compulsive Drug Seeking. https://doi.org/10.1093/oso/9780195300550.003.0009
509. Vanderver, A., Tonduti, D., Schiffmann, R., Schmidt, J., & Knaap, M. S. V. D. (1993). Leukodystrophy Overview – ARCHIVED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
510. Varı̀, M. R., Pichini, S., Giorgetti, R., & Busardò, F. P. (2018). New psychoactive substances—Synthetic stimulants. Wiley Interdisciplinary Reviews Forensic Science. https://doi.org/10.1002/wfs2.1197
511. Vataja, R., & Leppävuori, A. (2012). [Assessment and treatment of conversion disorder: the most fascinating borderline of psychiatry and neurology].. PubMed.
512. Velasco-Rey, M. C., Sánchez-Muñoz, M., Lopez, M., Trujillo-Borrego, A., & Sánchez-Bonome, L. (2012). Psychotic depression induced by Obstructive Sleep Apnoea Syndrome (OSAS): a case reported.. PubMed.
513. Velleman, S. L., & Mervis, C. Β. (2011). Children With 7q11.23 Duplication Syndrome: Speech, Language, Cognitive, and Behavioral Characteristics and Their Implications for Intervention. Perspectives on Language Learning and Education. https://doi.org/10.1044/lle18.3.108
514. Venkataraman, R., Patodia, S., & Thiriveedhi, R. N. (2023). Thrombocytopenia in the Critically Ill: An Animal with Several Heads. Indian Journal of Critical Care Case Report. https://doi.org/10.5005/jp-journals-11006-0089
515. Verhagen, E. H., Hesselmann, G. M., Besse, T. C., & Graeff, A. D. (2005). [Palliative sedation].. PubMed.
516. Verhoeff, M. C., Baat, C. D., Ahlberg, J., Manfredini, D., Winocur, E., Zweers, P. G., Rozema, F. R., Vissink, A., & Lobbezoo, F. (2020). Medications and addictive substances potentially inducing or attenuating sleep bruxism and/or awake bruxism. Journal of Oral Rehabilitation. https://doi.org/10.1111/joor.13061
517. Viola-Saltzman, M., & Musleh, C. (2016). Traumatic brain injury-induced sleep disorders. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s69105
518. Vitiello, B., Zuddas, A., & Masi, G. (2006). Pharmacologic treatment of children and adolescents with attention deficit hyperactivity disorder. CRC Press eBooks. https://doi.org/10.1201/b14454-11
519. Vivanco, E. F., Gómez, C. P., & Martínez, R. G. (2006). Patología orgànica por drogas de síntesis. Adicciones.
520. Volkow, N. D., & Wolf, A. (1991). THE USE OF POSITRON EMISSION TOMOGRAPHY IN IDENTIFYING AND QUANTIFYING RECEPTORS INVOLVED IN SCHIZOPHRENIA.. Brookhaven National Laboratory eBooks.
521. Wadhwa, R., & Khandare, M. (2014). Stress Management through Yoga. Global Journal of Human-Social Science.
522. Wakefield, J. C. (2015). DSM-5 substance use disorder: how conceptual missteps weakened the foundations of the addictive disorders field. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.12446
523. Walker, K., & Wilmshurst, J. M. (2010). An update on the treatment of Sydenham’s chorea: the evidence for established and evolving interventions. Therapeutic Advances in Neurological Disorders. https://doi.org/10.1177/1756285610382063
524. Walther, M., & Woods, D. W. (2010). Trichotillomania. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy1011
525. Watkins, C. V., & Peñailillo, B. V. (2004). Efectividad de un modelo de psicoterapia grupal desde la perspectiva constructivista - evolutiva en niños con trastorno de déficit atencional subtipo hiperactivo - impulsivo.
526. Weisholtz, D. S., & Dworetzky, B. A. (2014). Epilepsy and Psychosis.
527. Werner, F. M., & Coveñas, R. (2016). Additional Antidepressant Pharmacotherapies According to a Neural Network. Brain Disorders & Therapy. https://doi.org/10.4172/2168-975x.1000203
528. Wet, E. D. (2006). Dealing with traumatic events : social skills. SA pharmacist's assistant/South African pharmacist's assistant.
529. Wichaidit, B. T., Rask, C. U., & Østergaard, J. R. (2014). [Diagnosing functional seizures in children and adolescents].. Research Portal Denmark.
530. Wiegant, V. M. (1991). [Stress].. PubMed.
531. Wieland, C. (2008). Chronic and acute enactment: the passive therapist and the perverse transference. https://doi.org/10.4324/9780203891926-18
532. Williams, R. H., & Erickson, T. B. (2000). Evaluating Hallucinogenic or Psychedelic Drug Intoxication in an Emergency Setting. Laboratory Medicine. https://doi.org/10.1309/v3j8-3kw2-bpt1-fu15
533. Williams, R. H., Erickson, T. B., & Broussard, L. A. (2000). Evaluating Sympathomimetic Intoxication in an Emergency Setting. Laboratory Medicine. https://doi.org/10.1309/wvx1-6fpv-e2lc-b6yg
534. Winters, K. C., & Ingwalson, A. (2022). Internalizing and Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0006
535. Winters, W. D. (1976). Effects of Drugs on the Electrical Activity of the Brain: Anesthetics. The Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev.pa.16.040176.002213
536. Wise, E., Lyketsos, C. G., & Onyike, C. U. (2018). Aggression and Violence. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615371990.jl06
537. Woźniak, J., BOGACZ, R., Gaik, M., URAM, E., MAGDA, I., Womperski, K., & OSUCH, M. (2023). use of psilocybin in the treatment of psychiatric disorders – review. Journal of Education Health and Sport. https://doi.org/10.12775/jehs.2023.43.01.009
538. Wu, D., Liu, X., Yao, X., Yang, Y., Zhang, J., Yang, H., & Sun, W. (2022). Analysis of electroclinical features of nonconvulsive status epilepticus: a study of four cases. Acta Epileptologica. https://doi.org/10.1186/s42494-021-00073-x
539. Wyatt, J. P., Illingworth, R. N., Graham, C. A., Hogg, K., Clancy, M., & Robertson, C. E. (2012). Environmental emergencies. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199589562.003.0006
540. Yadin, E., & Foa, E. B. (2007). Cognitive Behavioral Treatments for Posttraumatic Stress Disorder. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511500008.013
541. Yang, S. S., Seet, R. C., & Lim, E. C. (2010). Chewing-induced Facial Dystonia. Annals of the Academy of Medicine Singapore. https://doi.org/10.47102/annals-acadmedsg.v39n9p740
542. Yarlagadda, A. R., Brown, A. B., & Clayton, A. H. (2007). Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611h
543. Yoshimura, S., & Imai, K. (1990). PATHOLOGICAL STUDY ON NEUROTOXICITY OF DRUGS. Journal of Toxicologic Pathology. https://doi.org/10.1293/tox.3.65
544. Young, W. B., Packard, R. C., & Katsarava, Z. (2007). Headaches Associated with Head Trauma. https://doi.org/10.1093/oso/9780195326567.003.0016
545. Zamorski, M. A., & Ward, R. (2000). Social Anxiety Disorder: Common, Disabling, and Treatable. The Journal of the American Board of Family Medicine. https://doi.org/10.3122/15572625-13-4-251
546. Zawilska, J. B., Santorek‐Strumiłło, E., & Kuna, P. (2010). [Nighttime eating disorders--clinical symptoms and treatment].. PubMed.
547. Zheng, Z., Zou, K., Huang, J., Yang, J., Zhou, J., Xiong, R., & Li, Y. (2023). Schizophrenia. https://doi.org/10.1007/978-981-99-4538-2_20
548. Zhou, D., & Yuan, T. (2019). Harnessing brain activity at adolescence prevents later schizophrenia development. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.13126
549. Zutshi, A., Math, S. B., & Reddy, Y. C. J. (2007). Escitalopram in Obsessive-Compulsive Disorder. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611c
550. Češková, E. (2018). Pharmacotherapy of cognitive dysfunction in depressive disorder. Neurologie pro praxi. https://doi.org/10.36290/neu.2018.057
551. Şahin, Ş., Ünsal, M. A., Çınar, N., & Karşıdağ, S. (2015). Olgular Temelinde Artmış İrkilme Yanıtının Gözden Geçirilmesi. Journal of Contemporary Medicine. https://doi.org/10.16899/ctd.75571
552. Šumarac-Dumanović, M., Micić, D., Macut, Đ. P., Kendereški, A., Zorić, S., Cvijović, G., & Pejković, D. (2002). Hipoglikemijski sindromi - dijagnostički i terapijski pristup i prikaz dva slučaja. ABC - časopis urgentne medicine.